N A N O T E C H - USA STOCKS - small and midcap - 500 Beiträge pro Seite

[opelmanta3]

XDSL (RFID NANOTECH ....)
http://www.mphasetech.com

http://www.mphasetech.com/ForbesWolfe.pdf

EMFP (NANOMASK)
http://www.emergencyfiltration.com/Product%20Page/Products.h…

MIVT ( HAp Nano-film Coating Technology )
http://www.mivtherapeutics.com/

SEHO (Homeland Security, and Nanotechnology)
http://www.senseme.com/scripts/about.htm

[opelmanta3]

[opelmanta3]

Emergency Filtration Products Receives Approval from United States Department of Defense for Its Filter Technology Platform
Monday January 10, 11:27 am ET
Company to Cancel Series "B" Warrants Pursuant to Financing Agreement


HENDERSON, Nev.--(BUSINESS WIRE)--Jan. 10, 2005-- Emergency Filtration Products Inc. (EFP) (OTCBB: EMFP - News) today announced that it has received confidential and official notification from the United States Department of Defense approving the use of its filter technology for the U.S. military. This notification included specific reference to the company`s protective masks as well as an interest to develop filtration systems for use in tanks, vehicles and shelter (buildings).
The company intends to work closely with the U.S. military and designated manufacturers to further the development of its filter technology, with the objective of including it into a number of products that would be used to protect U.S. military personnel worldwide.

"We are gratified and honored that the U.S. military has deemed our filter technology fit for use to protect U.S. military personnel," said Douglas K. Beplate, president, EFP. "We will continue to work diligently with the U.S. military, and any manufacturers with whom we are directed to collaborate, to incorporate our filter technology into any applications required by the military."

Separately, the company announced that it will cancel its Class B Warrants for the purchase of 2,000,000 shares of common stock pursuant to the terms of its financing agreement. The agreement allowed the company to effectively cancel the Class B warrants by the validation and acknowledgment, in the form of a letter or statement from the United States Department of Defense, that the company`s products are approved for military use and/or can be used in military applications.

[opelmanta3]

EMFP heute + 20%

[opelmanta3]

[opelmanta3]

http://nanotechwire.com/company.asp?cid=535

[opelmanta3]

XDSL bid .43

[opelmanta3]

XDSL .44

[opelmanta3]

XDSL .47

[opelmanta3]

http://www.smalltimes.com/


In more ways than one, it`s a delicate balancing act that mPhase Technologies Inc. wants to execute.

First is the company`s technology: making a nanobattery by placing droplets of water on filaments of silicon. A jolt of electricity then bursts the droplet, it soaks the silicon, and pent-up energy is released.

Then there is the company itself. Eight years old, mPhase was founded to sell telecommunications components. Leveraging that business to leap into the uncertain world of nanotechnology is quite a jump.

"Frankly, it`s really a branch into a new field," admitted Steve Simon, mPhase`s vice president of engineering.

Nobody scoffs at the goal. Working in partnership with Bell Labs, mPhase has demonstrated a proof-of-concept nanobattery crammed with filaments of silicon "nanograss" only a few hundred microns high and is working on a prototype that can illuminate a light-emitting diode. On Dec. 16, it reported that the military, oil industry and homeland defense expressed interest in using its nanobatteries to power sensors.

mPhase launched in 1996 as a maker of components and software for DSL service or other telecommunications lines, with a particular eye towards video to the home. It went public in 1997, trading under the ticker symbol XDSL. Although headquartered in Norwalk, Conn., the company had engineering labs in New Jersey, home to Lucent`s fabled Bell Labs. The two companies agreed in 2004 to work together on energy technology created at Bell Labs.

"The idea was to take stuff in the lab that was going nowhere from a commercial point of view, and focus it on a particular technology," Simon said. "We chose the battery technology."

The underpinning of the battery is the nanograss developed by Bell Labs scientists. Using standard lithography techniques, researchers carve silicon filaments several hundred microns high and 300 nanometers in diameter. The filaments are coated with water-repellent materials, so that droplets of liquid balance atop the nanograss but never touch them.

The droplets are electrolytes, brimming with ions. A jolt of heat or electricity then bursts the droplets; they spill onto the nanograss, the ions generate power, and the filaments carry the electricity to whatever device is attached.

The challenge, Simon said, is to tweak the mixture of coatings and droplets to ensure the largest "contact angle" – that is, to ensure the droplet soaks as much of the silicon as possible so it will generate the most power with the least stimulation.

Forging the correct nanostructures is one part of the process, "but the other part is getting the surface property correct," said Tom Krupenkin, a Bell Labs researcher working on the battery. "If you change one part of it, that changes the whole picture."

Bell Labs had been investigating the idea of a microscale chemical reactor for several years, Krupenkin said, but applications for a reactor proved elusive. Eventually, researchers thought of a battery: easy-to-understand, with well-known chemical properties.

At such small scale, mPhase`s batteries have several advantages, Simon said. Because the electrolyte is so close to the electrode (the silicon), they generate power faster than normal batteries; yet because the two surfaces never touch until activation, they should never corrode. Simon believes the nanobatteries` lifespan is at least 20 years.

Initial batteries are a centimeter square and 800 microns high, each called a "cell." Simon and Krupenkin want to stack the cells to power larger devices, and in theory they could be built directly into silicon devices such as RFID tags. What the batteries might ultimately cost, and how much power they could generate, remains to be seen.

Nanobatteries are a hot topic of research, although most work happens in academic or corporate labs. Dale Teeters, a University of Tulsa chemistry professor who studies nanobatteries, said a primary goal is to export the increased efficiency of nanobatteries to regular batteries, usually by building ever-smaller components. Exploiting nanoscale chemistry to create battery-like functions, as mPhase is trying to do, is a more exotic approach.

"It`s almost always about having nanoscale components," said Teeters, who was not familiar with mPhase`s specific work. He has created batteries with components down to 200 nanometers, although he needs atomic force microscopes to charge it.

"It seems more and more people are working on nanobatteries, however you define it," Teeters said.

[opelmanta3]

http://ragingbull.lycos.com/mboard/boards.cgi?board=XDSL&rea…

[1upandaway]

am tageshoch gekauft aber am ende zählt eh der verkaufskurs (ab in den norden damit siehe ragingbull)

[opelmanta3]

NEWS IST DA!!!! zurck auf .51


Seeing is Believing as Video News Reports Feature Nanobattery Built on Microscopic Nanograss Spears
Wednesday January 26, 10:43 am ET


NORWALK, Conn.--(BUSINESS WIRE)--Jan. 26, 2005--A nanobattery under development by mPhase Technologies (OTC:XDSL - News) will be featured in two video news service reports covering the nanotechnology field. Two production companies, ScienCentral and MAX World News are issuing informational news segments this week. The ScienCentral news clip will be aired on ABC TV affiliates nationwide. When available online, the news story will be posted on their web site, http://www.sciencentral.com/index.php3.
MAX World News distributed their video report via satellite yesterday to science and technology editors at more than 500 local news stations. The local science and technology editors will use the clip in their local programming to help people understand this exciting application for nanotechnology.

mPhase is commercializing the nanobattery application under license from Bell Laboratories, the R&D arm of Lucent Technologies (NYSE:LU - News). The battery uses nanograss built on silicon with spears that are almost invisible, with diameters of 270 nanometers. The videos explain the science underlying the batteries and show the proof of concept experiment of the nanobattery generating power.

Ronald A. Durando, CEO of mPhase Technologies, said, "There is nothing like a picture to help potential customers and investors understand the scale and potential of our nanobattery. The scale and anticipated long shelf-life of these batteries will enable new applications."

About mPhase Technologies

mPhase Technologies Inc. (OTC:XDSL - News) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. In telecommunications, the Company`s mPhase TV+ platform cost-effectively and reliably delivers entertainment digital television, high-speed Internet access, and traditional telephone service over existing copper telephone lines. mPhase also offers a growing line of innovative DSL component products, such as the Broadband Loop Watch, designed to help service providers lower the provisioning and operating costs associated with DSL. The company is bringing nanotechnology out of the laboratory and into the market with a planned innovative long-life power cell.

[erik der große]

Und ich wollte heute welche kaufen...
Jetzt weiß ich nicht ob wir nochmal tiefere Kurse sehen oder ob dass das Tief war!?

[pagitz01]

also ich habe gekauft....

thja was solls...hop oder trop.....


hab mir auch noch gtel zugelegt kennt ihr diese aktie....

[1upandaway]

tomorow upandaway

[opelmanta3]

http://www.sciencentral.com/articles/view.php3?type=article&…

video: http://www.sciencentral.com/articles/pop11.php3?video=real&v…

01.27.05



Imagine if a battery you bought today could be used twenty years from now. As this ScienCentral News video reports, a new discovery in nanotechnology could give batteries a very long shelf-life.

Longer Life

Even when you`re not using the devices they`re in, your batteries are losing as much as seven to ten percent of their power each year. The chemicals in traditional batteries react and slowly degrade with time.

Now, mPhase Technologies and Bell Labs, the R&D arm of Lucent Technologies, have teamed up to develop a type of "nano-battery" that can store and generate electric current, and that you may be able to use twenty years after the day you buy it.

"Regular batteries, the kind that most of us are familiar with, contain all the chemicals mixed together in the battery, so when we go get it off the shelf, the battery chemicals are all mixed together and have a certain shelf life," says Steve Simon, Executive VP of Research and Development at mPhase Technologies. "The thing that`s very novel about the nano-battery is that the chemistries are not mixed together…until you activate it, the battery does not dissipate any of its energy, so it has a very, very long shelf life and it gives it very interesting characteristics that regular batteries don`t have."

The research team has shown that it`s possible to postpone the chemical reaction that causes traditional batteries to degrade, by levitating liquid droplets of an electrolyte above the surface of a battery using tiny stalks of silicon, called nanograss. The "blades" of nanograss are roughly a thousand times thinner than a human hair. No power is used until the device is turned on—at which point the electrolyte droplet sinks to the bottom of the nanograss and causes a reaction to occur, producing electricity.


Nanograss
image: Lucent Technologies
Thomas Krupenkin, physicist at Lucent Technologies, explains the process: "You have the nanograss and you have a liquid sitting on the tips of nanograss. An electrode, which sits on the bottom of nanograss, is separated from the liquid…in order for the battery to work you have to have the electrode and electrolyte touching each other, because only this way you can have a chemical reaction. Here, they are not touching each other so there is no chemical reaction. And as a result, the battery does not degrade with time whatsoever. However, if you drive the liquid down, it starts wetting the bottom of the structure and now you have a direct contact. Now your chemical reaction starts working and your battery starts producing current."

Krupenkin and his team are working on ways of stacking these nano-batteries together to make them even more powerful. The battery is also being fine-tuned for different applications; one that Simon envisions is a supplemental cell phone battery. "If I`m on an airplane and my rechargeable battery has died, I have no electrical outlet and I`m sort of stuck," says Simon. "Well, I can imagine a time where attached to a little slot in your cell phone will be one of our little nano-batteries. I need 10 minutes to complete this phone call, here`s this little nano-battery, [it] kicks in, I`m able to make my phone call."

[Petronius]

SALVE!

Leute, Leute. Das war wohl ein wenig übertrieben.
Wochenlang dümpelt diese finanzschwache Firma bei 30 Cent herum und explodiert, weil es angeblich zwei Fernsehberichte gezeigt werden sollen. Tags darauf konkretisiert MPhase, dass diese zwei Fernsehberichte lediglich auf Webpages anzusehen sind.....und der Kurs fällt wieder. Beide Bewegungen übrigens mit massiven Umsätzen.

Verdammt, es sind schon wieder zu viele dumme Zocker unterwegs, es wir Zeit für einen neuen Crash, der diese Idioten wegspült.

Ich interessiere mich schon seit einiger Zeit für mphase, hier mal ein paar kleine Anmerkungen.

1. mphase ist extrem defizitär
2. Man hat gerade 14 Mio Aktien zu 0.20 Cent zur Finanzierung herausgegeben, die mit einer mehrjährigen Kaufoption zu 25 Cent verknüpft sind.
3. Produkte und Produktaussichten interessant
4. Bisher in der Vermarktung immer schwach gewesen

Nur Nano ist nicht genug!!!!

Hier noch der Link zur Finanzierungsanzeige: http://biz.yahoo.com/e/050121/xdsl.ob8-k.html
Hier ein anderer SEC-Bericht: http://media.corporate-ir.net/media_files/irol/11/115986/rep…

Ball flach halten!
Petronius

[Petronius]

SALVE!

Ehm, hatte wohl Recht! Der Kurs steht nun bei 34 Cent, ich glaube in dieser Region ist der Wert ohne WIRKLICHE Neuigkeiten auch gut aufgehoben.

Beobachten!

Petronius

[opelmanta3]

EMFP sieht heute weiter gut aus .53 höchst

[opelmanta3]

http://www.stamfordadvocate.com/business/scn-sa-businessfeb0…


As cable TV invades phone companies` turf, Norwalk`s mPhase helps the telcos retaliate
Email this story

Printer friendly format

Top Stories
As cable TV invades phone companies` turf, Norwalk`s mPhase helps the telcos retaliate



By David Jastrow
Special Correspondent

February 6, 2005


Cable companies have cut into telephone provider profits with Internet-based phone services, but they won`t go down without a fight. Today, they are marketing premium television packages through partnerships with satellite television providers.

Systems from Norwalk`s mPhase Technology soon may help place more TV power into the cradle of telephone companies.

"Our software allows telephone companies to offer services that are a lot more feature rich," said Mary Whelan, executive vice president of marketing and communications at mPhase. "We can give consumers better control."

Using a homogeneous Internet Protocol infrastructure, mPhase`s "TV+" allows telephone providers to give every TV customer a unique identification code, just like a personal computer connected to the Web. This address gives phone companies the ability to deliver services cable companies cannot, Whelan said.

"The IP address allows the telecoms to create new services," she said. "It gives viewers the ability to interact and control what they watch more effectively. It means (telephone companies) can begin to offer services that are much more feature-rich and differentiated from one-way broadcast content delivery."

Cable and satellite operators can deliver broadcast TV, high-definition, video-on-demand and pay-per-view services. But mPhase`s software takes these capabilities further.

The technology adds personal video recorder services that allow subscribers to view live or recently broadcast programs on demand. It also adds two-way action for video games and viewer selection of camera angles.

mPhase`s software has e-commerce features, so viewers can buy products they spot while watching their favorite shows and live events on television.

Most importantly, it enables telecoms to air TV newscasts or high school sporting events that are enticing to local communities. IP addressing also lets phone companies provide targeted advertising, giving them more local advertising opportunities and sponsorship dollars.

"The industry is maturing, but we set up standards that allow telephone companies to mix and match computers seamlessly," Whelan said. "With our technology, telephone companies are not locked into a proprietary environment. They can use different kinds of hardware and organize content in a flexible manner. The consumer controls the experience."

Bob Larribeau, senior analyst specializing in telecommunications for Sunnyvale, Calif.-based IT researcher Multimedia Research Group, said providing IP-based technology to telephone companies is an emerging market set to take off. He said mPhase`s services should be valuable to small telephone companies serving rural markets.

"Most rural telephone companies are behind the curve in terms of video services," Larribeau said. "The key advantage they can provide over satellite is local content. If a telephone company can broadcast local high school football and basketball games, people want to watch that."

One concern with mPhase`s software is the possibility that having IP addresses placed on consumer TVs would leave them vulnerable to the computer virus attacks faced by PC users.

mPhase`s technology is designed to protect from such attacks, said Phil Thompson, executive vice president of product management.

"We do lots of things in-network to protect them from denial of service attacks," Thompson said. "We have very constrained in-points that are not as open as PCs. Our software uses IP addresses, but it`s not like turning a TV into a PC."

However, there are no guarantees.

"Anybody who tells you not to worry about hackers and virus attacks on IP networks is crazy," Larribeau said. "But set-top boxes are not Internet appliances, so they are not out on the Internet that much."

mPhase has good timing with its product launch, as telcos are increasingly eager to fight cable companies whose long customer reach is extending ever further into the domain of telephone providers.

Locally, Cablevision System Corp.`s Optimum unit began offering Internet-based telephone service in most of Stamford and much of Fairfield County via cable modems last year. The service is sold at a cheaper price than traditional telephone service.

The nation`s largest cable company, Comcast Corp., announced early last month that it, too, would plunge into the telephone fray with its own Voice over Internet Protocol phone services. The technology allows cable companies to offer unlimited local and long distance phone service at $30 to $40 a month.

Cablevision`s Optimum offers Internet phone service as part of a $90 bundle that also features digital cable and high-speed Internet access.

VoIP provider Vonage Holdings Corp. charges an even lower $24.99 monthly fee, too cheap for most traditional phone companies to compete on price.

At an investor conference in Phoenix early last month, Comcast Chief Executive Officer Brian Roberts said the company could generate more than $3.8 billion in revenue within five years from telephone services if the cable giant meets its target of attracting 8 million subscribers.

The company expects to market the Internet phone service to 15 million homes by the end of this year and almost all of its 40 million customers within 18 months. This would be a big boost for Comcast and a major threat to telephone companies.

"There is going to be a profound change in what a phone is in a home, and we`re going to be part of that process," Roberts said in an interview with business news service Dow Jones & Co.

As competition heats up, so likely will business for companies such as mPhase.

The publicly traded firm (OTC: XDSL), which mostly sells digital subscriber line equipment -- its TV services are delivered over DSL -- generated sales of $4.6 million in its fiscal 2004, a 193.4 percent increase over $1.6 million in fiscal 2003.

However, its net loss widened to $7.8 million in 2004, compared with a loss of $6.6 million a year earlier.

To date, mPhase`s activities have centered on designing, building and testing a suite of broadband communications software and equipment, but it has not yet generated substantial revenues from the products, according to the company`s latest annual report.

Headquartered in Norwalk, with locations in New York City and Atlanta, mPhase was started in 1996 as a spin-off of MicroPhase, a military products manufacturer and filtering software developer.

The mPhase TV+ system was developed with the Bell Labs division of Lucent Technologies Inc. The company`s key competitors are Alcatel, Next Level Communications, which recently became a division of Motorola, and units of several other technology vendors.

In December, the company published its "As You Like It Service Guide," a planning tool that telephone company strategic planners can use to deliver digital interactive TV services. The document is available on the Internet after registering on the mPhase Web site, mphasetech.com.

Telephony, a leading trade news magazine, recently stated that mPhase Technologies "moved into what is largely a next logical step in its development by launching a services creation strategy designed for telecos competing against incumbent cable and satellite providers in the video market."

Despite challenges, Larribeau said the company is poised for growth.

"You are going to see a lot more about telephone companies offering TV services," he said. "It`s an important new market and mPhase is pretty well positioned. They offer a more comprehensive approach than most of their competitors and an interesting ability to do customization. They have to do a good job with all clients. If they can do that, they should do well."

[opelmanta3]

XDSL in businessweek.com

als energy nanotech play

[opelmanta3]

http://www.taglichbrothers.com/equityuniverse/companies/mpha…

[opelmanta3]

ALTI mit news über nanobatteries.....xdsl läüft mit...

[opelmanta3]

mPhase Researcher will report on Nanobattery at the Nano Science and Technology Institute
Friday February 11, 9:41 am ET


NORWALK, Conn.--(BUSINESS WIRE)--Feb. 11, 2005--mPhase Technologies Inc. (OTC: XDSL - News) today announced that its lead researcher, Victor Lifton, will present a paper, "Atoms to products - a nanostructured novel battery," at the Nano Science and Technology Institute Conference and Trade Show in Anaheim, California.
Dr. Lifton will report on the progress of the mPhase plan to fabricate nanotech-based batteries, which can generate electric current. The project is based on a joint program with Bell Labs, the R&D arm of Lucent Technologies.

The novel battery is based on a Bell Labs discovery that liquid droplets of electrolyte will stay in a dormant state atop microscopic structures called "nanograss" until stimulated to flow, thereby triggering a reaction producing electric current.

"We are especially excited about the ability to use various battery chemistries and take advantage of the special characteristics of Nanograss," Lifton said.

Future batteries based on this technology have the potential to deliver far longer shelf life and better storage capacity than existing battery technology. Potential initial applications for this technology may include defense, industrial, healthcare, and consumer electronics. mPhase is also targeting the nanobattery for use in a technically-improved, lighter

[opelmanta3]

XDSL .75 im höchst heute bei sehr gutem volumen...

ALTI geht runter XDSL geht rauf....

[Petronius]

SALVE!

Ich kann nicht verstehen, wie diese Ankündigungen zu einem Papier die Kurse so beflügeln. Der Tätigkeitsbereich von mphase ist schon länger bekannt, eine Nano-Batterie ist bisher nicht fertiggestellt. Aber vielleicht liest man aus der gesteigerten Marketingtätigkeit, dass ei solches Produkt bald fertig sein könnte. Schade, dass ich bei 35 Cent keinen Mut hatte einzusteigen....

Petronius

[__MarketMaker__]

wann kommt der jahresbericht 04 für mPhase???

hab keine kennzahlen gefunden

[opelmanta3]

MIVT .33

[opelmanta3]

MIV Therapeutics Inc. and SagaX Medical Technologies Inc. sign Letter of Intent for Next-Generation Embolic-Protection Technology
Tuesday February 22, 5:39 pm ET


VANCOUVER, Feb. 22 /PRNewswire-FirstCall/ - MIV Therapeutics Inc., (OTCBB: MIVT - News) and SagaX Medical Technologies Inc. (SagaX), announced today that they have entered into a letter of intent regarding SagaX` next generation embolic-protection technology for stroke patients. The parties hope to negotiate and execute definitive agreements regarding the transaction within the next few weeks.
Led by Dr. Dov Shimon , SagaX Inc. is developing a proprietary filter with stent in the aorta to prevent stroke from emboli. Stent is a small metal scaffold inserted into the artery, emboli are blood clots that are formed in the heart and travel in the blood stream. They are a major cause for strokes the third most common cause of death and the most common cause of disability.

"MIVT looks forward to working with SagaX to conclude this agreement and making this new technology available to medical practitioners in many major world markets," said Alan Lindsay, MIV Therapeutics President and Chief Executive Officer. "With the addition of this technology, MIVT will be favorably poised to enter the lucrative field of endovascular/interventional products which include advanced neuro-interventional clinical applications. The MIVT technology portfolio will be further enriched by the acquisition of related intellectual property developed by SagaX."

[opelmanta3]

XDSL webcast

http://www.vcall.com/CEPage.asp?ID=90668

[opelmanta3]

SEHO

SENSE Holdings, Inc. and Intier Automotive Closures Inc. Sign Letter of Understanding to Evaluate Biometrics for Use in Automobiles
Tuesday March 1, 8:30 am ET
Biometric Technology Can Be Used to Access and Operate Motor Vehicles


FORT LAUDERDALE, Fla., March 1 /PRNewswire-FirstCall/ -- SENSE Holdings, Inc. (OTC Bulletin Board: SEHO - News; SENSE), a leading provider of biometrically secured authentication and identification systems, announced the company has signed mutual non-disclosure agreements and a letter of understanding with Intier Automotive Closures Inc. of Newmarket, ON and Novi, MI. The companies will investigate and evaluate the applications and integration of certain biometric technology for automotive use. SENSE will supply to Intier Automotive Closures biometric hardware and software, mainly fingerprint sensors and software matchers for integration with customer or showcase demonstration vehicles or systems. Intier Automotive Closures will internally work on the installation of prototypes and conduct market research and testing to determine suitability for the automobile industry. Intier Automotive Closures is a leading Tier One supplier to companies such as GM, Ford, DaimlerChrysler and Nissan. Intier Automotive Closures has expertise in vehicle closure modules and systems including door modules, handles, window systems, power closing systems and latching systems. SENSE Holdings, Inc. has over six years` experience in the biometric arena and will assist Intier Automotive in the implementation and evaluation process. The contemplated biometric automotive application allows for the user or vehicle owner to use their fingerprint to access and operate the vehicle. No key or Fob is necessary. The applicable biometric patent encompasses all biometric technologies including voice, iris, face and fingerprint recognition.
ADVERTISEMENT


"Biometrics is an evolving technology that Intier Automotive Closures would look to integrate with existing automotive systems," stated Dale Karolak, VP of Product Engineering for Intier Automotive Closures Inc. "This technology offers convenience and security with no physical device to carry or lose," added Dr. Karolak.

"Intier Automotive Closures is the premier player to help introduce new technologies to market, and we at SENSE feel biometric technology offers the automotive consumer tremendous benefits," stated Dore Perler, CEO of SENSE Holdings, Inc. "Because this patented technology communicates directly with the on-board vehicle computer, speed and distance limitations can be programmed or adjusted to each individual driver."

SENSE actively seeks partners to expedite the integration of its explosives detection and biometric authentication and identification technologies into aviation, banking and finance, education, food preparation, gaming, garment, health care, hotel, insurance, law enforcement, manufacturing, military, public safety, security, restaurant, retail, and transportation applications, with industry-specific calibration.

[opelmanta3]

MIVT .50 im höchst

heute NEWS:

MIV Therapeutics Inc.`s HAp Nano Stent Coating Demonstrates Excellent Biocompatibility and Safety in Coronary Arteries
Tuesday March 8, 6:00 am ET


VANCOUVER, British Columbia--(BUSINESS WIRE)--March 8, 2005--MIV Therapeutics Inc. (OTCBB:MIVT - News), a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, announced today the successful completion of pilot preclinical studies of hydroxyapatite (HAp) coated stents in pig coronary arteries. The histopathology studies that followed angiographic and intravascular ultrasound evaluation confirmed excellent biocompatibility and safety of its proprietary hydroxyapatite (HAp) coating for vascular applications.
ADVERTISEMENT


The 28-day safety study was performed on four different formulations of MIVT`s biocompatible hydroxyapatite (HAp) nano-film coating specifically designed for cardiovascular stents, vascular applications, and use in a broad range of other implantable medical devices. Stents coated with MIVT`s proprietary coating demonstrated superb safety and healing properties when implanted in pig coronary arteries.

"The stents coated with hydroxyapatite have demonstrated excellent biocompatibility and safety of our proprietary coating technology. The low amount of produced neointima ranks with the best contemporary bare metal stents and some drug-eluting stents described in literature utilizing a similar experimental setting. This remarkable result gives us a solid foundation for pivotal pre-clinical safety studies and subsequent clinical studies," said Alan Lindsay, Chairman, President and CEO of MIVT.

The animal trial was conducted at the Methodist DeBakey Heart Center, Houston, Texas, by Greg L. Kaluza, M.D., Ph.D., FACC, who summarized: "The study was extremely successful in yielding consistent and clearly interpretable data despite its exploratory character. All four variants of the hydroxyapatite coated stents have deployed very easily, had favorable presentation in angiography and intravascular ultrasound, and demonstrated excellent safety and biocompatibility by histology. It has to be noted that such biocompatibility of coated stainless steel surface has been rarely found in polymer stent coatings currently dominating the field. The results obtained in the present pilot study with hydroxyapatite, a material naturally occurring in the body, offer a promise of a uniquely favorable safety and biocompatibility profile, rarely matched in the endovascular setting."

The histology studies were supervised by Fred J. Clubb, Jr., DVM, Ph.D., Director of Research at the Cardiovascular Pathology Laboratory, Texas Heart Institute, Houston, Texas, who concluded in his report: "Four studied stent groups coated with different coating technologies did not induce excessive vascular changes. Results of this study suggest that the stents coated with MIVT Hydroxyapatite coating could be safe for clinical trials."

Neither of the above institutions, nor the investigators involved in the above study, had any vested interest in the sponsors of the study.

Dr. Dov Shimon, Chief Medical Officer of MIV Therapeutics and Heart Surgeon, added, "In all investigational groups evaluated in this study the endothelialization of all study stents was complete at 28-days. Moreover, there was no significant residual fibrin visible on the luminal surface or around the stent struts. All the histology parameters were very uniform and on par with the bare metal stents. Bare metal stent surface has been so far unmatched in vascular compatibility. Competitive coatings specifically designed with an objective to decrease thrombogenicity, such as heparin or phosphorylcholine, have failed to be clinically superior to stainless steel. Thus, this equivalence of HAp coating to stainless steel is an extremely valuable and encouraging finding."

About the Methodist DeBakey Heart Center and Texas Heart Institute, Houston, Texas

The Methodist DeBakey Heart Center and the Texas Heart Institute, Houston, Texas, are leading clinical, academic and scientific research institutions. Both institutions are globally recognized as leading cardiovascular centers. Pioneering work and contributions in the fields of heart surgery, congenital heart disease, aortic surgery, heart transplantation, vascular surgery, and invasive cardiology have placed these centers as pillars of excellence.

[opelmanta3]

MIVT
EMFP

[opelmanta3]

http://www.smallcapinsights.com/si/




Welcome to SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other information about the Smallcap investment marketplace. We strive to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com will include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis.

The Smallcap world is unique: it’s filled with development-stage companies that are commercializing cutting-edge technology and executing bold business plans. There are high-growth opportunities available. To make the best decisions, investors need two things: information and insight. That’s what SmallcapInsights.com is all about.





Today SmallcapInsights.com presents an audio interview with Alan Lindsay, who is Chairman, President and CEO of MIV Therapeutics (OTCBB: MIVT), a biotech company that’s developing an exciting patented technology to improve the effectiveness and functionality of cardiovascular stents and other implanted medical devices. One of MIVT’s central areas of innovation is the development of a revolutionary coating technique that can significantly improve the body’s acceptance of implanted cardiovascular stents and other biomedical devices. This proprietary ultra-thin coating is derived from a unique biocompatible material called Hydroxyapatite (HAp); it’s made from the same substance that makes up bone mineral and the matrix of teeth. As a result, the body’s immune system doesn’t reject medical devices that are coated with HAp. This proprietary ultra-thin coating has been has been shown to significantly inhibit the body`s inflammatory response and other serious complications that can arise in connection with implanted medical devices. But there’s more: HAp is porous, which enables it to be used as a drug-eluting coating. That means the coating itself can be filled with medicines that can be delivered with high precision directly to the area of tissue around the stent. Industry commentators agree that drug-elution is the way of the future for the worldwide stent industry. MIVT has also made a couple of very recent planned acquisition announcements -- including that of Sahajanand Medical Technologies, one of the world’s largest manufacturers of advanced coronary stents – that have the potential to immediately boost the Company into the top tier of the international stent industry. Enter your email address in the upper left-hand corner of this page to hear the interview.

[opelmanta3]

MIV Therapeutics Receives Government Grant to Expedite Development of Proprietary HAp Stent Coating for Drug Delivery Technologies
Tuesday March 22, 4:01 pm ET


VANCOUVER, B.C.--(BUSINESS WIRE)--March 22, 2005--MIV Therapeutics Inc. (MIVT: OTCBB) announced today that its wholly-owned subsidiary, MIVI Technologies Inc., that is involved in the research and development of multilayer coating technologies with drug eluting capability for cardiovascular stents and other implantable devices, has received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents". The National Research Council approved MIVI`s application following an in depth familiarization with the advanced concept of novel technologies proposed by MIVI, and a review of the Company`s organizational and fiscal capability to carry on with the proposed USD 1 million+ R&D program.
ADVERTISEMENT


"Receiving IRAP support for our research and development program will help us bridge the financial needs associated with our drive towards commercialization of our technologies., said Alan Lindsay, Chairman and CEO of MIV Therapeutics Inc. "In order to achieve financial assistance from The National Research Council the Company had to meet variety of stringent requirements set forth by the guidelines of the program, which were later verified during numerous on-site visits by the IRAP team of technical and business reviewers.. Approval of our application comes at a time when the Company is gearing towards clinical trials of its proprietary Hydroxyapatite (HAp) nano-coating technology, and when we are simultaneously aggressively pursuing the development of the next generation of fully biocompatible coating for a variety of applications on medical devices. IRAP funding will provide welcome support to these corporate development strategies".

Mr. Arc Rajtar, V.P. Operations, who also heads the MIVI R&D team and coordinates technical cooperation with the University of British Columbia commented, "We are very pleased with the news regarding approval of our application by NRC IRAP experts. IRAP funding will be used to support our demand for personnel who will help us with their experience and expertise to meet the objectives of this ambitious program. The multilayer composite coatings will offer drug release characteristics which can be "engineered" to accommodate a broad variety of drugs and their specific applications, in a manner which is demanded by the medical practitioners."

Dr. Tom Troczynski, Ph.D., Professor of Ceramics at The University of British Columbia and MIVT Vice President of Coatings added, "IRAP grant supports MIVI`s research program focusing on development of advanced composite coatings complimenting MIVT`s proprietary Hydroxyapatite (HAp) coating technologies. The program will develop a new generation of multilayer drug eluting coatings combining the superb biocompatibility already achieved by our proprietary HAp coatings with expanded applications and enhanced properties offered by the composites."

[Petronius]

SALVE!

Na also. Die Kurse von MPHASE kommen wieder auf ein normales Niveau zurück. Jetzt bin ich Lauerstellung.

Zur Erinnerung nochmals, dass man vor einigen Wochen
14 Mio Aktien zu 0.20 Cent zur Finanzierung des Defizits herausgegeben hat, die mit einer mehrjährigen Kaufoption zu 25 Cent verknüpft sind.

Petronius

[opelmanta3]

Emergency Filtration Products Signs NanoMask Distributor for Wholesale and Retail Markets in the United States and Southeast Asia
Monday March 28, 11:34 am ET


HENDERSON, Nev.--(BUSINESS WIRE)--March 28, 2005--Emergency Filtration Products Inc. (EFP) (OTCBB: EMFP - News) today announced that it has signed a non-exclusive distribution agreement with Manteca, Calif.-based 2H Distributors (http://www.2hdistributors.com/) to distribute the company`s NanoMask to both retail and wholesale market segments in the United States and internationally. 2H Distributors has already placed its initial stocking order of 10,000 NanoMasks and 50,000 replacement filters.
ADVERTISEMENT


In the United States, 2H Distributors will launch a marketing campaign for the NanoMask, and will be seeking retail outlets throughout the country, with particular emphasis on marketing to airport retail stores that cater to customers flying to the Pacific Rim. Internationally, 2H Distributors` wholesale marketing plans entail forming partnerships with a number of consumer products distributors in Southeast Asian markets such as Vietnam and Thailand.

"I am excited not only about the potential market for the NanoMask, but perhaps more importantly, about its ability to help save lives in a time when the avian flu has been deemed -- by no lesser authority than the World Health Organization -- to have the potential to kill millions worldwide," said Douglas Heath, president, 2H Distributors.

"The recent concern about the H5N1 virus, better known as the avian flu, has sparked a great deal of interest in our NanoMask," said Douglas K. Beplate, president, EFP. "While we have been quietly selling this product to consumers who have requested it, we have made no effort to launch a large-scale campaign for this product. Instead, we believe that our interests will be better served by entering into distribution agreements such as this one with 2H Distributors, as well as pursuing large corporate and retail opportunities."

About NanoMask

(http://emergencyfiltration.com/Product Page/NanoMask.htm)

[opelmanta3]

MIV Therapeutics Claims of Total Biocompatibility of Hydroxyapatite Confirmed by Independent Scientific Studies
Thursday April 14, 6:00 am ET
Japanese Studies Report Blood Compatibility, Protein Adsorption and Thrombus-Free Performance of Hydroxyapatite


VANCOUVER, British Columbia--(BUSINESS WIRE)--April 14, 2005-- MIV Therapeutics, Inc. (OTCBB: MIVT - News) a developer of next-generation biocompatible stent coatings and drug delivery technologies, has summarized the results of two independent Japanese studies that found strong blood compatibility, adsorption of proteins, and overall biological safety of hydroxyapatite in blood. The two studies add important independent substantiation to MIVT`s own reports of exceptional biocompatibility and safety of the Company`s proprietary hydroxyapatite-based coating technology for cardiovascular stents and medical devices.
ADVERTISEMENT


MIVT has developed proprietary technology that use hydroxyapatite (HAp) to create advanced biocompatible and drug-eluting coatings for cardiovascular stents and other implantable medical devices.

Two independent Japanese studies found that HAp demonstrated exceptional performance and safety across several tested parameters in tests involving human blood samples, significantly bolstering and validating MIVT`s proprietary technology and product development initiatives in multi-billion-dollar markets for coronary stents, and other medical devices, such as implantable drug-delivery systems. The studies provide additional validation of MIVT`s claims of exceptional biocompatibility and safety of the Company`s proprietary HAp-based coating technology, recently reinforced by positive outcomes of comprehensive animal studies. MIVT`s HAp technology is entering the final stages of evaluation in preparation for commercial introduction for use as an advanced coating for cardiovascular stents and other medical devices.

"Both studies confirmed MIVT`s long-standing expectations and findings regarding the exceptional biocompatibility and safety of hydroxyapatite," said Mr. Lindsay. "Observations by the Japanese scientists are totally in line with the outcomes of our own comprehensive biocompatibility studies performed on stents with MIVT`s proprietary HAp coating by the independent testing authority, Toxicon Corporation. Preliminary conclusions from our comprehensive animal studies on hydroxyapatite-coated stents, which we are currently conducting, also confirm the total absence of undesirable side effects when hydroxyapatite is in contact with blood in cardiovascular applications. We expect to publish more detailed information on the progress of our advance studies in the near future."

In one of the Japanese studies, scientists from the Biomaterials Laboratory, Faculty of Engineering at Okayama University in Japan examined the blood compatibility and protein adsorption of hydroxyapatite and hydroxyl-carbonate apatites. Blood compatibility and clotting properties were evaluated with three key parameters which are known to have a detrimental effect on potential blood clotting: active partial thromboplastin time (PTT), prothrombin time (PT), and the amount of fibrinogen (Fib).During the study titled "Selective protein Adsorption and Blood Compatibility of Hydroxy-carbonate Apatites", samples of hydroxyapatite were exposed to fresh plasma extracted from human blood. Protein adsorption was also evaluated in solutions of bovine serum albumin (BSA) to simulate a healthy person, and in solutions to test the effects in a person suffering from amloidosis, a condition in which insoluble protein fibers tend to deposit in organs, preventing their proper function. This condition is considered one of the key factors that promote chronic infection or chronic inflammatory disease frequently encountered during cardiovascular interventions involving stent implantation or other procedures. The study confirmed total biocompatibility and safety of hydroxyapatite when exposed to direct contact with blood.

The scientists at Okayama University concluded: "The clotting properties (partial thromboplastin time, prothrombin time and the amount of fibrinogen) for plasma in contact with samples of hydroxyapatite and plasma which did not have any contact with hydroxyapatite were the same."

An earlier study performed by another group of scientists at the Bioceram Division of Kyocera Corporation in Gamo, Japan, evaluated deposition of fibrins and adhesion of platelets to the hydroxyapatite-coated titanium when exposed to anticoagulated blood, and to washed platelet suspension (WPS). Uncoated, commercial grade titanium plate was used as an experimental control element.

The study concluded: "No thrombus was observed on hydroxyapatite-coated samples, possibly because of the high adsorption of heparin." Heparin, a medication that inhibits reactions that leads to the clotting of blood and the formation of fibrin clots, was applied during this study at a level typically used during medical procedures. In this context, protein adsorption refers to the important bonding phenomenon that occurs between proteins or protein-based drugs and hydroxyapatite, enabling improved drug-eluting characteristics. A thrombus is a blood clot that forms within a blood vessel, and remains attached to its place of origin; such blood clots are a significant source of vascular complications.

[Petronius]

SALVE!

Am 23.3. habe ich vor dem aufgeblähten Kurs gewrnt,
jetzt sind wir wieder bei 29 Cent.

Petronius

[opelmanta3]

MIV Technologies, Inc. Rated `Outperform,` Target $1.53 by Investrend Affiliate Beacon Equity Research
Tuesday April 26, 8:30 am ET


NEW YORK--(BUSINESS WIRE)--April 26, 2005--(Investrend Research Syndicate) MIV Technologies, Inc. (OTCBB: MIVT - News) has been rated "Outperform," with a price target of $1.53 by Investrend Research affiliate Beacon Equity Research. The report is authored by Senior Research Analyst, Shailesh Dhuri.
The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com

In the report Mr. Dhuri writes, "MIV is focusing on developing biocompatible device coatings, therapeutic stent technologies and drug delivery systems for drug-eluting applications... The Company holds worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is naturally found in the body as a main constituent of bone.

Currently, the Company claims to be the only firm which is undergoing trials with a fully biocompatible hydroxyapatite-based coating for stents. Tests conducted so far indicate a high probability that human bodies will accept MIV`s HAp-coated stents without rejection, clotting or inflammation - the usual problems with stents.

The firm`s drug-eluting stent was introduced in 2003 as a possible solution to bare metal stents` inherent problems. Drug-eluting stents assist in reducing the restenosis to only 8% (from 25% with bare stents). Currently, there are two drug-eluting stents which have received marketing clearance from the FDA: the Cypher stent from Cordis (NYSE: JNJ - News) and the Taxus stent produced by Boston Scientific (NYSE: BSX - News).

MIV`s HAp biocompatible-coated stent could offer a very attractive alternative to bare-metal stents in countries where most patients cannot afford to use drug-eluting stents. It has the potential to reduce restenosis rates and inflammatory reactions at a much lower price.

[opelmanta3]

SENSE Holdings Signs Asperian for Representation for Biometrics and Security Solutions in Mexico, Colombia and Venezuela
Tuesday April 26, 8:30 am ET
- Asperian C.A. Will Expose Security Solutions to Corporate, Government, Education and Military Clients


FORT LAUDERDALE, Fla., April 26 /PRNewswire-FirstCall/ -- SENSE Holdings, Inc. (OTC Bulletin Board: SEHO - News; SENSE), a leading provider of biometrically secured authentication and identification systems, announced that the company has signed its first representative as a result of the recent LatinChannels conference in Queretaro, Mexico. Asperian C.A., a global leader providing consulting services to the Information Technology industry, will expose SENSE Holdings and its security-based technology solutions to enterprise-level government agencies and corporate clients throughout Mexico, Colombia and Venezuela. Asperian, based in Mexico City, has 120 employees and has been in business since 1985. Asperian has strategic alliances with IBM, Peoplesoft, and J.D. Edwards, providing installation, maintenance, operational monitoring, technical support and information security services. Asperian plans to offer the SENSE security solutions for integration into existing systems and new installations. Asperian will sell the CheckPrint TA/AC (Time and Attendance / Access Control), the SenseTag RFID asset tracking system, and the Sense Prison administrator solution. The SENSE security solutions are TCP/IP-based (network ready), while offering tremendous flexibility for integration of third-party components, and easily integrate with current infrastructures. Asperian has placed its initial order with SENSE Holdings for demonstration systems for Access Control, Time and Attendance, and RFID asset tracking.
"The security products presented to us by SENSE are exactly what the Latin American market requires," stated Joaquin Rosado, Director General of Asperian. "The need for access control, employee tracking, and RFID solutions are becoming more demanding, and we are excited to represent SENSE in this new venture," added Mr. Rosado.

"We are very pleased to be working with Asperian, and their experience and expertise in the Latin American market is essential when offering new secure technologies," stated Dore Perler, CEO of SENSE Holdings, Inc. "We feel they will be an excellent partner to represent SENSE products internationally," added Mr. Perler.

[Chlorophyll]

Da staunt man. Der Wert zieht doch wieder an.
Zur Zeit 2:12am bei +26% auf 0.33 bei einem Umsatz von 2`906`981.
Vielleicht nur ein Strohfeuer??

[gony2]

Der Umsatz stimmt auf jeden Fall und in D ziehen die Kurse und auch die Umsätze nach

[gony2]

Wie sieht es denn hier aus?
beschäftit sich noch jemand mit mphase oder schon wieder alles vorbei.
Ich meine wir zeigen relative Stäreke die letzten Wochen, was doch ein gutes Zeichen ist...........

[smoothtrader]

[posting]16.802.332 von gony2 am 04.06.05 16:37:48[/posting]Warte gelassen darauf, daß die TechWerte wieder anspringen.

Kann nicht mehr lange dauern.

[gony2]

mPhase Technologies Executive Stresses Need to Make IPTV Simple and Relevant to Average User

LITTLE FALLS, N.J.--(BUSINESS WIRE)--June 6, 2005--

At "Service Delivery Platforms 2005", a Light Reading Live! Event,
Phil Thompson Says Service Creation is Key Telco Advantage

Telephone companies have the means to improve their competitive position by taking advantage of improved service creation platforms for delivering easy-to-use, highly customized interactive television and video services, according to a senior executive with mPhase Technologies, (OTC:XDSL), a pioneer in internet television (IPTV).

Phil Thompson, executive vice president-product management for the mPhase TV+ System, told an industry forum that open standards, rather than proprietary systems that limit innovation, are the key to rapidly creating highly personalized and compelling services for premium subscribers.

"Popular culture and diverse interests quickly fade with each passing wave, yet IPTV delivery platforms today are too static to keep up with contemporary trends and impulsive audiences," said Thompson. "Telcos can seize the advantage of their carrier-grade broadband systems to rapidly morph their service offerings to this new market reality - catering to people`s whims and impulsive behavior."

Thompson was a speaker at "Service Delivery Platforms 2005," a Light Reading Live! Event held today in Chicago.

Phone companies must contemplate a variety of inherent conflicts to making service secure, yet open to many developers, rich with features, yet intuitive to the average person. Still, he noted that architectural models with standard and familiar Web tools are now available for balancing the new requirements. A comprehensive service creation environment can have built-in flexibility for rapid provisioning and billing consistent with legacy systems while incorporating innovations from multiple vendors.

Relying on standard programming protocols like HTTP (HyperText Transfer Protocol), XML (eXtensible Markup Language), SOAP (Simple Object Access Protocol), and WSDL (Web Services Description Language), telco personnel now have ready tools for a variety of administrative, market research and provisioning systems to achieve the desired flexibility for profiting from rapidly-changing consumer habits, said Thompson. As examples, he cited a variety of portal services to quickly cater to impulse shoppers wanting to buy pizza, engage in multi-screen games, contact customer support or access value-added services like email, chat or custom music downloads.

"There is no disputing that rich services reduce customer churn, and the way to compete today is to create a suite of rapidly-evolving content that suits today`s fickle audience," said Thompson.

mPhase`s As You Like It(TM) service creation platform addresses many of the requirements that Thompson outlined. To obtain further detailed information about creating customized content packages, telco representatives are urged to register on the mPhase web site at http://mphasetech.com/asyoulikeit.htm

About mPhase Technologies

mPhase Technologies Inc. (OTC: XDSL) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. In telecommunications, the Company`s mPhase TV+ platform cost-effectively and reliably delivers entertainment digital television, high-speed Internet access, and traditional telephone service over existing copper telephone lines. mPhase also offers a growing line of innovative DSL component products, such as the Broadband Loop Watch, designed to help service providers lower the provisioning and operating costs associated with DSL. The company is bringing nanotechnology out of the laboratory and into the market with a planned innovative long-life power cell.

More information is available at the mPhase Web site at www.mPhaseTech.com.

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

[i2fan]

nur noch 0,21 . Ist doch jetzt ein einstieg wert, denke ich.

[opelmanta3]

MIV Therapeutics Announces Availability of Research Report Projecting 300% Share Value Increase in 12 Months
Tuesday June 28, 5:10 pm ET
Report by SISM Research & Investment Services Affirms `Speculative Buy` Recommendation and Stock Price of $1.50


VANCOUVER, British Columbia--(BUSINESS WIRE)--June 28, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the availability of an extensive research and investment report by SISM Research & Investment Services that projects a 300% increase in share appreciation, and reaffirms a Speculative Buy/4 recommendation of the Company`s stock with a 12-month target price of $1.50.
ADVERTISEMENT


The SISM "Company Insight!" report, authored by leading market analyst Ernest C. Schlotter, concludes that the company`s fully biocompatible, ultra-thin HAp coating technology positions it to become a world leader in the coated medical device market.

The report provides a detailed overview of MIVT`s proprietary Hydroxyapatite (HAp)-based biocompatible stent coatings and novel drug-delivery solutions designed to address known weaknesses of current drug-eluting systems. The report outlines MIVT`s intellectual property portfolio, which was strengthened recently through exclusive licensing of four additional technologies from the University of British Columbia. It also reviews key research milestones achieved to date.

For example, the report states: "In June 2004, MIVT commissioned Toxikon Corp., of Bedford, MA, to complete a full range of twelve biocompatibility studies on its proprietary HAp coating technology. All twelve studies were successful and confirmed HAp`s exceptional biocompatibility."

The report adds: "MIVT`s HAp stent coating also demonstrated excellent performance and biocompatibility in all key areas at three-month follow-up of porcine trials, paving the way for MIVT to enter the lucrative drug-eluting stent market."

The report also expands on MIVT`s key investment and business highlights, including the completed acquisition of SagaX Medical Technologies and an agreement to acquire advanced stent manufacturer Sahajanand Medical Technologies, one of the world`s largest manufacturers of advanced coronary stents outside of the U.S. The pending acquisition of Sahajanand is expected to bring MIVT approximately $20 million in revenues in its first year, as well as immediate access to Sahajanand`s world-class production facilities and well-established distribution network.

The report concludes: "Based on the Company`s strong management team and outstanding proprietary coating technology, MIVT is clearly undervalued, and we reaffirm our Speculative Buy/4 recommendation for the stock of MIV Therapeutics with a 12-month target price of $1.50."

[luto9]

Insiderkäufe am 20.27.29.6.2005

[mobilepro]

luto meinst du miv therapeutics?

[luto9]

ne

wir sind doch bei xdsl oder liege ich da falsch

[opelmanta3]

Die Experten von "Invest Inside" empfehlen die Aktie von MIV Therapeutics (ISIN US55306V1061/ WKN 798618) zu kaufen.

Nach Einschätzung der Experten stehe die kanadische Biotechschmiede MIV Therapeutics mit seiner neuartigen Technologie zur Beschichtung von Stents vor dem Durchbruch in der kardiovaskulären Forschung. Anleger könnten hier an einem Unternehmen mit extrem niedriger Bewertung und riesigem Umsatzpotenzial partizipieren.

MIV Therapeutics habe sich im weltweit boomenden Wachstumsmarkt für kardiovaskuläre Medizintechnologie in den letzten Jahren still und heimlich eine ausgezeichnete Marktposition in einem lukrativen Nischensegment erworben. Das Unternehmen entwickle biokompatible Beschichtungen für passive und medikamentenbeschichtete Applikationen für kardiovaskuläre Stents und andere implantierbare Medizinprodukte. Das Wachstum für kardiovaskuläre Stents betrage durchschnittlich 25% pro Jahr.

MIV Therapeutics verfüge über ein erfahrenes Management und einen renommierten wissenschaftlichen Beirat, die als leitende Organe der Firma Vertrauen schaffen würden. Im Board würden weltweit bekannte Finanzierungsprofis sitzen, die sich dafür einsetzen würden, dass die Finanzierungsspielräume gesichert seien und die Expansion des Unternehmens vorangetrieben werde.

Das Unternehmen sei aber nicht nur in der Stent-Branche aktiv sondern auch im Segment medizinischer Anwendungen zur Verabreichung von Medikamenten. Anwendungsgebiete seien hier unter anderem Harnwege, Nieren, Speiseröhren und die Verabreichung von chemotherapeutischen Medikamenten bei der Behandlung von Krebs. Die Kooperation mit der University of British Columbia (UBC) sei durch ein Lizenzabkommen umrahmt, das es MIV erlaube, seine Technologie und das dort entdeckte Produkt HAP weltweit zu vermarkten.

Ziel von MIV sei es, das vorhandene Produktportfolio deutlich zu erweitern und eine beeindruckende Medikamentenplattform zu entwickeln. Es bestehe kein Zweifel, dass dieser Technologie die Zukunft gehöre und in 5-10 Jahren nahezu jede auf Stenten basierende Operationsmethode auf die Produkte von MIV zurückgreifen werde. Mit dem derzeitigen Fortschritt in der Entwicklung der beschichteten Stent-Technologien könne MIV schon in naher Zukunft zu einem bedeutenden Player in dieser Branche aufsteigen. Es sei sogar wahrscheinlich, dass zukünftig die Fabrikation von klassischen Metallstenten immer mehr zugunsten der Beschichtungsmodelle von MIV zurückgedrängt werde.

Das Unternehmen habe eine Marktkapitalisierung von derzeit nur knapp über 25 Millionen USD. Die finanzielle Liquidität liege zurzeit bei ungefähr 2 Millionen USD. Die von MIV entwickelte ultradünne Beschichtung sei von einem bis dato unbekannten biokompatiblen Material, dem Hydroxiapatit (HAp), abgeleitet worden. HAp verfüge über entzündungshemmende Eigenschaften. Damit könne unter anderem das häufig auftretende Problem der Restenose (chirurgische Gefäßrekonstruktion) im Zusammenhang mit eingepflanzten Medizinprodukten deutlich reduziert werden. Dies sei in der Tat eine wissenschaftliche Revolution mit sensationellem Potenzial, die bisher von Anlegern nahezu übersehen worden sei. Eine deutlich Kurskorrektur nach oben scheine daher nur eine Frage von wenigen Wochen oder Tagen zu sein, weil bereits aktuell ein positiver Newsflow zu beobachten sei, der auffällig an Intensität zugenommen habe und deutlich mache, dass der Durchbruch unmittelbar bevorstehen könnte.

Das Unternehmen sei auf dem aktuellen Kursniveau von 0,45 Euro massiv unterbewertet. Sowohl aus fundamentaler als auch charttechnischer Sicht stehe hier mindestens ein Test der 0,60 Euro Marke an. Hier dürfte ein erster starker Widerstand liegen, der bei guter Nachrichtenlage natürlich dynamisch durchbrochen werden könne und anschließend sofort Potenzial bis auf 1 Euro freisetze. In dem bis dato weitgehend unentdeckten Nischenplayer stecke auch kurzfristig erhebliches Wachstums- und Kurspotenzial. MIV Therapeutics biete daher aktuell eine exzellente Gelegenheit für risikobewusste Investoren, an einer Firma mit niedriger Bewertung und Umsatzpotenzial von mehreren Milliarden Dollar frühzeitig zu partizipieren.

Die MIV Therapeutics-Aktie wird von den Experten von "Invest Inside" zum Kauf empfohlen. Analyse-Datum: 04.07.2005

[opelmanta3]

MIVT wird uns reich machen.....

$ 3 noch im sept.

[opelmanta3]

na gut dann wirds halt oktober...

[opelmanta3]

bitte wieder augen auf EMFP richten...sehr schone volumen bei steigenden kursen seit freitag....


NANOmasks ---> H5N1 vogelgrippe etc.


http://www.buynanomask.com/







$$$

[opelmanta3]

http://www.turiyagateway.com/

[opelmanta3]

http://birdfluprotection.com

[maxeddi]

Solar Energy hat von 0,50 auf 1,23 innerhalb von 10 Tagen um 146% zugelegt, und steigt immer noch. Calypte hat sich von 0,11 auf 0,26 fast verdreifacht, innerhalb von ein paar Tagen. Diese beiden Aktien haben gemeinsam, dass sie von stock-report VORHER empfohlen wurden und mit ein wenig Zeitverzögerung konnte man an diesen Veränderungen Teil haben. Wie hoch MPhase geht, bleibt abzuwarten, und wie lange man investiert bleibt und zu welchem Kurs man aussteigt muss jeder selbst wissen. Fakt ist, dass in USA derzeit ein Ausbruch nach oben stattfindet, bei steigendem Volumen. Fakt ist auch, dass vor diesem Ausbruch mit über 7,5 Mio gehandelten Aktien der höchste Umsatz seit Januar war. M.E. wird sich die Aktie kurzfristig toll entwickeln, heute 10 % den Amis vorwegzunehmen, halte ich für einen guten Kurs bis 15:30 Uhr. Wer vorsichtig ist, versucht pari reinzukommen (0,217 akt RT Kurs), wer mutig ist, bezahlt bis zu 0,238 heute, was in den kommenden Tagen noch günstig sein wird. Bin mal auf die USA Impulse gespannt.
(Zur Vollständigkeit in den drei aktuellen Threads gestellt)

[opelmanta3]

http://www.2hdistributors.com/

[maxeddi]

Ist egal ob heute oder morgen, übermorgen hast Du 100% mehr in der Tesch!Zur Zeit könnt Ihr noch mal nachlegen, einige von uns sind zittrig und denken, in bereits 20% gestiegene Pfauntsch-Werte einzusteigen bringt mehr. Zu RT 0,226 seid Ihr dabei. Wie siehts das vorbörslich aus ?? Jemand Infos?

[maxeddi]

Kannst Du bitte mit Deinen Vogelmasken in nen anderen Thread gehen? Bist echt lästig!

[Kaufmonster]

Ask und Bid ziehen Vorbörslich schon etwas an

[maxeddi]

Eröffnung für 5 min. zu 0,26$, dann kräftiger Anstieg auf über 0,35$. Wetten dass...?

[maxeddi]

0,275 USD bezahlt

[Petronius]

SALVE!

Zur Abkühlung der Gemüter nochmal zwei alte Beiträge von mir. Vielleicht einmal nachrecherchieren.....

Petronius
--------------
23.3.2005:
SALVE!

Na also. Die Kurse von MPHASE kommen wieder auf ein normales Niveau zurück. Jetzt bin ich Lauerstellung.

Zur Erinnerung nochmals, dass man vor einigen Wochen
14 Mio Aktien zu 0.20 Cent zur Finanzierung des Defizits herausgegeben hat, die mit einer mehrjährigen Kaufoption zu 25 Cent verknüpft sind.

Petronius


-----

28.1.2005:

SALVE!

Leute, Leute. Das war wohl ein wenig übertrieben.
Wochenlang dümpelt diese finanzschwache Firma bei 30 Cent herum und explodiert, weil es angeblich zwei Fernsehberichte gezeigt werden sollen. Tags darauf konkretisiert MPhase, dass diese zwei Fernsehberichte lediglich auf Webpages anzusehen sind.....und der Kurs fällt wieder. Beide Bewegungen übrigens mit massiven Umsätzen.

Verdammt, es sind schon wieder zu viele dumme Zocker unterwegs, es wir Zeit für einen neuen Crash, der diese Idioten wegspült.

Ich interessiere mich schon seit einiger Zeit für mphase, hier mal ein paar kleine Anmerkungen.

1. mphase ist extrem defizitär
2. Man hat gerade 14 Mio Aktien zu 0.20 Cent zur Finanzierung herausgegeben, die mit einer mehrjährigen Kaufoption zu 25 Cent verknüpft sind.
3. Produkte und Produktaussichten interessant
4. Bisher in der Vermarktung immer schwach gewesen

Nur Nano ist nicht genug!!!!

Hier noch der Link zur Finanzierungsanzeige: http://biz.yahoo.com/e/050121/xdsl.ob8-k.html
Hier ein anderer SEC-Bericht: http://media.corporate-ir.net/media_files/irol/11/115986/rep…

Ball flach halten!
Petronius

[opelmanta3]

MAXEDDI:

mein thread meine stocks

dies ist mein XDSL MIVT SEHO EMFP thread
falls du soweit noch nicht gekommen bist...


BTW: XDSL .32 (+23%)

[opelmanta3]

EMFP

.56 zu .57 vorbörslich

des schaut gut aus

[opelmanta3]

.74 im höchst für heute

[opelmanta3]

http://abcnews.go.com/Health/Flu/story?id=1182529&page=1





As concerns over a bird flu epidemic surge, some people are seeking reassurance by getting prepared with cover — face coverage.

Manufacturers and distributors of the so-called nanomask say that with every report of bird flu concerns, sales spike. The masks, specifically designed to keep out biological hazards, including the bird flu virus, started selling swiftly following the comments last week of U.N. health chief David Nabarro who said that a mutation of the virus affecting Asia could trigger new, widespread outbreaks.



Full Coverage


Bush Presses Vaccine Makers on Bird Flu
Bird Flu Concerns Make Masks Hot Commodity
Merck: Cervical Cancer Vaccine Effective
And with every new report about the virus, people buy more masks.

"We currently are attempting to produce between 100,000 and 200,000 masks a week," said Doug Beplate, founder and president of Emergency Filtration Products, based in Henderson, Nev. "Now they`re going out as soon as we make them. I don`t see us catching up to the demand in the near future."


Better Than n95 Standard?

The Centers for Disease Control and Prevention recommends that health care workers who handle contagious patients, including those infected by SARS and the avian flu, wear masks that meet the n95 rating under the CDC`s National Institute for Occupational Safety and Health. This means that the respirators filter out at least 95 percent of airborne particles during testing using a "most-penetrating" sized particle of 0.3 microns.

"Research indicates that n95 respirators provides higher protection than a standard surgical mask," said Roland Berry Ann, acting program manager for respiratory protection at NIOSH. "The fit of the mask is also very important. Workers have to keep in mind if you can breathe around the mask, then the filter isn`t going to help."

Beplate claims his masks do better thanks to a coating that reacts to contaminants at the mask surface. He says that electric charges within the nanoparticle coating and among a contaminant react, rendering the contaminant inactive.

"It works kind of like a magnet," Beplate said, but declined to go into further detail, citing copyright concerns.

[opelmanta3]

pt2:

Beplate has not submitted his masks for CDC or NIOSH ratings because he wants to maintain intellectual privacy but he says an independent laboratory, Nelson Laboratories in Salt Lake City, has tested the product and found it is 99.99 percent effective at filtering particles as small as 0.027 microns. The laboratory is registered under the Food and Drug Administration.




NIOSH`s Berry Ann confirms his laboratory has not received any samples of the mask for testing and approval, but he and his co-workers are aware of the technology and are researching it.




Clean Hands, Clear Health


No matter how well a mask works, however, health care workers stress that the most important protection against infection is personal vigilance.



"Masks may offer people a security blanket," said Michael Zimring, director of the Wilderness and Travel Medicine Center at Mercy Medical Center in Baltimore and co-author of the book "Healthy Travel." "But just putting on a mask isn`t going to do it. You have to do everything else, too. Keep your hands clean, stay hydrated and get enough rest."

[maxeddi]

Erster Kurs unverändert 0,26 Dollar...scheint sich heute nicht viel zu tun.

[Quadra]

@ maxeddi,

Denk daran THOR MINING!!


Gruß Quadra

[maxeddi]

Ja wär nochmal ne Investition wert, aber heute nicht.
MPhase 0,255 -2% scheint weiter nordwärts zu gehen, hoffentlich hält hier die 0,19€ !

[maxeddi]

Steigt auf 0,211!

[maxeddi]

Danke! hab nachgelegt.

[Petronius]

[posting]18.150.656 von Petronius am 05.10.05 17:22:06[/posting]SALVE!

T J A !

Petronius....

[opelmanta3]

MIV Therapeutics Files both US and International Patents for Breakthrough Smart III Nanoparticle Drug Delivery System
Friday October 7, 4:01 pm ET
Cutting-Edge Nanotechnology Particulate System Could Revolutionize Drug Delivery Methods to Treat Major Diseases


VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 7, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, today announced the filing of landmark US and international Patent Cooperation Treaty (PCT) patent applications for the newest member of its advanced "Smart" drug delivery systems, designed to meet the individual needs of millions of patients.
ADVERTISEMENT


MIVT`s cutting-edge system combines nanotechnology and pharmaceutical solutions, to produce nano-to-micro sized particles that provide an unprecedented, highly versatile platform for localized delivery of a variety drugs to treat a range of conditions. This system is designed to expand the boundaries of drug delivery adaptability with broad application possibilities and customized medical treatments. Called "Smart III," this novel particulate composite technology allows for the storage and delivery of one or more drugs within each particle`s nano-layer.

Smart III technology could moreover be applied to medical device coatings, tablets, capsules, and other drug delivery methods to treat a diverse range of diseases, from cancer to HIV to cardiovascular disease, said Dr. Dean-Mo Liu, Chief Scientist of Drug Delivery Technologies at MIVT in Vancouver, Canada. "The release of a drug or drugs is now controllable via slow diffusion and/or layer-by-layer degradation of this novel nanostructure, with possible drug release patterns ranging from slow diffusion to a burst release, depending on the clinical need. In addition, Smart III nanoparticles can be administered in various forms, including via drug injection, inhalation, oral pill, spraying, or capsule."

Advanced drug elution technologies are absorbing an increasingly large share of the global biotechnology marketplace. Drug eluting medical device coatings, for example, have produced a paradigm shift in clinical care since their commercial debut in the last couple of years. The U.S. Dept. of Commerce estimates a burgeoning domestic market for advanced drug delivery systems of $86 billion in 2007, and more than $150 billion globally.

"We believe that this invention represents a major breakthrough in pharmaceutical technology and eventually, in patient care," said Dr. Liu. "It advances the possibilities of drug delivery to targeted tissues and can apply to a range of drugs, especially water-insoluble agents such as anti-cancer drugs, protein drugs and anti-HIV drugs. In addition, this unique structure could be suitable to deliver contrast agents for extended periods of time, to enhance medical diagnostic tests."

The Smart III patent filing represents the latest "Smart" proprietary technology developed by MIVT. Earlier members of the "Smart" family of drug delivery technologies were specifically designed for advanced medical device coatings on implantable medical devices. The newest member, however, has much broader potential use for drug delivery purposes because of its novel and highly-customizable particulate structure.

Arc Rajtar, Chief Technology Officer at MIVT, said, "This breakthrough drug delivery solution puts MIV Therapeutics firmly within the ranks of leading innovators in the burgeoning market for next-generation drug delivery capabilities. We are very excited by the potential of this remarkably flexible technology, which brings the promise of superior drug delivery performance."

MIVT`s "Smart" technologies are under development at MIVT`s Vancouver-based research and development facility under the stewardship of Dr. Liu. The proprietary technology is entirely owned by MIVT.

[opelmanta3]

EMFP:

Vogelgrippe erreicht Türkei und Rumänien

[Aptamilla]

[posting]18.208.331 von opelmanta3 am 10.10.05 08:39:09[/posting]Vogelgrippe:Hemispherx/HEB(906543),Phase 3 vor Zulassung(Ampligen)!MfG Apta

[opelmanta3]

Emergency Filtration Products To Increase Production of NanoMask to Meet Growing Demand Caused by Avian Flu Threat
Monday October 10, 8:01 am ET


HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 10, 2005--Emergency Filtration Products, Inc. (EFP) (OTCBB: EMFP - News) today announced that it is planning to increase production of its NanoMask due to a surge in demand. The company has placed an initial order for the production of 500,000 filters from a West Coast based supplier. The filters, which are expected to be manufactured within the next several weeks, will then be shipped to EFP`s Henderson, Nevada facility where they will be enhanced with nanoparticles and packaged.



Concurrently, the company expects to receive 50,000 mask shells from Taiwan and has placed an initial order for an additional 100,000 mask shells from its Taiwanese supplier. At the first stage of its production ramp up, EFP expects be able to assemble up to 50,000 masks and nano-enhance 200,000 filters per week. The final assembly will be done in Henderson as soon as EFP receives the filters and mask shells. EFP plans to further increase its production capacity as demand dictates.

"Over the past few weeks we have experienced a strong increase in orders for the NanoMask, which we believe is due to the growing threat of a possible avian flu pandemic," said Douglas K. Beplate, President, EFP. "As a result, and due to a number of potentially large orders from a number of medical products distributors in the United States and abroad, we are gearing up production capacity to meet the growing demand for the NanoMask."

[opelmanta3]

http://www.welt.de/data/2005/10/11/787480.html

[opelmanta3]

http://www.commondreams.org/headlines05/1010-08.htm



http://www.commondreams.org/headlines05/1010-08.htm

[opelmanta3]

http://www.nsti.org/press/PRlist.html

NEWS von

MIVT
XDSL
EMFP

[opelmanta3]

EMFP .80

[opelmanta3]

October 14, 2005
Nanotech Battles Bird Flu
By Colin C. Haley


Health officials around the world are sounding the alarm about Bird Flu. The virus has killed 60 people in Asia and its discovery in Europe this week has heightened fears of a pandemic.

While the medical community works to eradicate Bird Flu, several nanotech (define) and IT firms say their products could help control it.

"Nanotechnology will undoubtedly be used in some form -- either as a vaccine, a treatment, a delivery method for a drug, or as a means to detect, control or limit the spread of the influenza," Adrian Burden, CEO of Singular ID, told internetnews.com.

Singular ID was founded in December and makes magnetic tags that give a "fingerprint" to objects. The tags are similar to RFID (define) chips, but are smaller, stronger and aren`t susceptible to signal interference, Singular ID said.

The Singapore startup has also developed readers and a secure database that can be accessed using a GPRS (define) or satellite phone.

So how does a company founded to help track and authenticate products thwart Bird Flu? While the readers and database are programmed to gather data from Singular ID tags, they could just as easily work with biosensors.

"A specific biosensor can be used out in the field to detect Bird Flu in an animal, and the data can be quickly sent to a central database for secure storage and data analysis," Burden said.

The combination of the technologies saves time because first-responders wouldn`t have to drive samples back to the lab and allows for a broader picture of geographic areas.

Singular ID is exploring these possibilities with biosensor developer BiMAT. New York venture capital firm Advance Nanotech funds both companies.

Burden added that if field tests are developed, Singular ID tags could be used on animals that have been checked. In addition, the company would work with a drug maker to ensure that no counterfeit vaccines find their way to market.

Given that its less than a year old, Singular ID products are still being developed. The firm hopes to have an evaluation kit available for potential customers in the second quarter of 2006.

It also hopes that any system it develops for Bird Flu could also be used on other illnesses, such as malaria, dengue fever or AIDS.

In contrast, Emergency Filtration Products` (Quote, Chart) offering is on the market now. The Henderson, Nev., company said that demand for its NanoMask is surging amid flu fears.

EFP said its NanoMask uses a filtration system combining nanoparticles and filters to capture bacterial and viral microorganisms. The company has ordered 500,000 filters from its supplier which will be shipped to the company`s Nevada facility, enhanced with nanoparticles and packaged.

"Over the past few weeks we have experienced a strong increase in orders for the NanoMask, which we believe is due to the growing threat of a possible avian flu pandemic," Douglas K. Beplate, president of EFP, said in a statement.

Christine Peterson, founder of the Foresight Nanotech Institute, notes that in the fight against viruses its hard to categorize emerging technologies as nanotechnology or biotechnology, but devices like nanotech biosensors could be important going forward.

"As we look in decades to come, nano will be the ultimate answer to dealing with these viruses -- they are nanoscale machines."



http://www.internetnews.com/ent-news/article.php/3556471

[opelmanta3]

MIVT
EMFP

beide gut am laufen....


Erster Fall von Vogelgrippe in Griechenland


Das Landwirtschaftsministerium in Athen gab bekannt, daß das Vogelgrippe-Virus auf der griechischen Insel Chios nahe der türkische Küste festgestellt wurde. Es stand nicht fest, ob es sich um den für Menschen besonders gefährlichen Vogelgrippe-Typ H5N1 handelte. WELT.de

[opelmanta3]

Press Release Source: mPhase Technologies Inc.


mPhase Technologies Has $0.374 SqueezeTrigger Price On Projected 8,584,664 Shares Shorted in 2005 According to Buyins.net Research Report
Monday October 17, 12:42 pm ET


LITTLE FALLS, N.J.--(BUSINESS WIRE)--Oct. 17, 2005--BUYINS.NET / www.buyins.net, is initiating coverage of mPhase Technologies (OTCBB: XDSL - News) after releasing the latest short sale data through October 14th, 2005. From January through mid-October of this year, an approximate amount of 8,584,664 shares of XDSL have been shorted for a total dollar value of nearly $3.2 million. The XDSL SqueezeTrigger price of $0.374 is the volume weighted average short price that all shorts are short in shares of XDSL. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://buyins.net/squeezetrigger.pdf .
Month Total Volume Short Volume Avg. Price Short Dollar Value

January: 31,017,400 1,240,696 $0.425 $527,295.80
February: 45,420,200 1,816,808 $0.552 $1,002,878.02
March: 24,957,900 998,316 $0.474 $473,201.78
April: 10,762,800 430,512 $0.326 $140,346.91
May: 27,768,800 1,110,752 $0.278 $308,789.06
June: 10,729,600 429,184 $0.272 $116,738.05
July: 12,584,700 503,388 $0.262 $131,887.66
August: 7,711,100 308,444 $0.243 $74,951.89
September: 22,699,400 907,976 $0.235 $213,374.36
October: 20,964,700 838,588 $0.262 $219,710.06

Total: 214,616,600 8,584,664 $0.374 $3,210,664.37

* short volume is approximated using a proprietary algorithm
** average short price is calculated using a volume weighted
average short price.

XDSL On OTCBB Naked Short Threshold List

On List Off List # Days

February 3rd March 11th 26
April 29th June 21st 37
July 20th August 15th 19
August 26th September 6th 7
October 7th Currently on list 6

mPhase Technologies has been on the OTCBB Naked Short Threshold list 5 different times and has currently been on the list for 6 consecutive trading days as of October 14th. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer`s total shares outstanding. SEC Regulation SHO under the Securities Exchange Act of 1934 mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.

[Aptamilla]

[posting]18.315.240 von opelmanta3 am 17.10.05 18:26:28[/posting]Am besten läuft Hemispherx(HEB)-906543.Heute über 20 Prozent plus an der AMEX.HEB kurz vor der Zulassung(Phase 3)-Vogelgrippe!

[opelmanta3]

APTAMILLA: das ist falsch am besten läuft nanovericides: NNVC +75% oder so...


aber ich bleib lieber bei den soliden steigern

EMFP
MIVT

[opelmanta3]

Beacon Equity Research Initiates Coverage of Sense Holdings Targeting Share Price to Approximately Double to $0.75
Wednesday October 19, 4:01 pm ET
Report Details Company`s Advanced Biometric and Explosive Detection Technologies for Global Homeland Security Markets


FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct. 19, 2005--Sense Holdings, Inc. (OTCBB:SEHO - News; FWB:OUP), a developer of next-generation biometric and explosive detection security technologies for government and commercial security markets, today announced that Beacon Equity Research, a paid investment research firm, has initiated research coverage of the Company, issuing an extensive initial report that includes a long-term $.75 projected target share price, representing an approximate doubling of the Company`s recent share value.
ADVERTISEMENT


The Beacon report provides a detailed analysis of Sense Holdings` business model and management`s strategic vision to develop innovative solutions in several multi-billion-dollar segments of the Homeland Security market, including the $4 billion biometrics market area. It also spotlights the Company`s program to develop next-generation detection devices designed to screen for explosives, chemical and biological weaponry, and narcotics to target those fast-growing multi-billion-dollar global markets.

The report notes that the field of biometrics is considered by many industry experts to be the future of authentication for a range of core security and related applications. "While passwords based on text can be forged or stolen, authentication based on a person`s fingerprint, iris scan, or facial recognition will always be unique," according to the report. "The Company`s innovative product line has broad-based applications in the military, government and private sectors - all of which have a rapidly growing interest in biometrics and other security technologies."

In addition to possessing significant intellectual property in the biometric field, Sense Holdings has also recently announced plans to enter the rapidly-growing business of explosives detection, the report noted. The Company has also acquired exclusive worldwide patent licenses for chemical sensing for all security applications based on the advanced field of micro-electro mechanical sensors (MEMS) technology. Sense is developing significant intellectual property designed to lead to the development of devices to detect explosives and other potentially dangerous compounds.

"Sense Holdings is developing a handheld MEMS multi-substance detector that will have the capabilities of detecting explosives, chemical and biological substances and narcotics," the report noted. "The product will find usage in the government sector as well as for security-related applications such as airport security."

Research to develop Sense`s initial multi-substance detector is being conducted in cooperation with the prestigious Oak Ridge National Laboratory. "The device promises to be highly accurate and will likely reach the market in the next 12 to 18 months," the report states.

In an effort to increase innovation and revenue growth, Sense Holdings is currently in the process of integrating its business operations to create new categories of security and safety products not currently offered in the homeland security market, the Beacon report noted. "The Company is integrating its explosives detection technologies with its biometric authentication and identification technologies. With the successful integration of Sense Holdings` biometric and explosives detection technologies, the Company will be able to develop industry-specific applications for the following areas: Homeland Security, aviation, banking and finance, food preparation, gaming, health care, hotel, insurance, law enforcement, manufacturing, military, public safety, security, restaurant, retail and travel."

Beacon is a fee-based, comprehensive investment research firm, focused primarily on the smallcap sector. Among the key investment highlights cited in its 15-page analysis of Sense Holdings:

The market for biometric-based integrated security technologies is projected to reach $4 billion by 2006;
During the next few years, the industry is expected to achieve a growth rate of 25%;
The Company has acquired a substantial portfolio of intellectual property, including several patents;
The Company`s focus on proprietary software could significantly increase its market position over the Company`s competitors; and
Sense Holdings is planning to launch a new product to improve explosive detection capabilities available to the marketplace.
"Sense Holdings has spent a significant amount of resources on research and development, which has positioned it to now benefit from its intellectual property portfolio and patents by launching new and innovative products."

Sense`s stock is currently undervalued, according to the report, with an average share price inclined to rise next year and even more over the long-term - particularly given that the firm "has accumulated significant Fortune 100 clients, as well as numerous smaller clients, which should help it facilitate more revenue." To read the full text of the report, produced under compensation terms described below, please visit http://www.BeaconEquityResearch.com.

[opelmanta3]

Sense Holdings Spotlights Breakthrough Homeland Security Technology in Audio Interview with HomelandInsights.com
Thursday October 20, 3:30 am ET
CEO Reviews Company`s Proprietary Biometrics Security Solutions and Prototype Portable Explosives Detector for Airports


LOS ANGELES, Oct. 20, 2005 (PRIMEZONE) -- HomelandInsights.com, http://www.homelandinsights.com, the online source for exclusive investor information in the homeland security and defense market, announced today that it will debut an audio interview with Dore Perler, CEO of Sense Holdings, Inc. (OTC BB:SEHO.OB - News) (FWB:OUP), a developer of next-generation biometric and explosive detection security technologies for government and commercial security markets.
ADVERTISEMENT


In a far-ranging interview, Mr. Perler discusses Sense Holdings` innovative technology leadership in the emerging $4 billion biometric and micro-sensor identification space, as well as its strategic initiatives to enter additional critical homeland security market segments.

``The products and technology we`re developing at Sense Holdings are intended to address some of the fastest-growing areas of the Homeland Security marketplace, including advanced forms of identification, and the growing need for advanced explosive detection capabilities at airports and other locations,`` said Mr. Perler. ``I appreciate the opportunity to communicate with investors about our work in these areas in the HomelandInsights.com interview.``

Sense Holdings` primary business operations have focused on the design, development and manufacturing of biometric technologies for human identification and authentication, access control, and time and attendance systems. But now, the Company has also set its sights on a major new target - an integrated explosives detection technology that integrates the Company`s biometric authentication and identification expertise.

Among the Company`s major customers are some of the world`s largest public and private organizations, including the U.S. Army, the U.S. Department of Corrections, Federal Express, and American Airlines. Sense`s latest strategic initiative -- combined with the Company`s proven business and technology track record -- position it for opportunity in the security sector. To hear the full streaming audio interview free of charge, please visit: http://www.HomelandInsights.com.

[opelmanta3]

mms://media.sitestream.com/trilogy-capital_sitestream_com/op…

[opelmanta3]

mPhase Technologies Cited in Newsletter Article, ``Blue Chips Stack Up on Nanotech``
Thursday October 20, 9:00 am ET
Forbes/Wolfe Nanotech Report Discusses Firm`s Collaboration with New Jersey Nanotechnology Consortium


NORWALK, Conn.--(BUSINESS WIRE)--Oct. 20, 2005--In a lead article of the September, 2005 issue of Forbes/Wolfe Nanotech Report, an industry newsletter, mPhase Technologies, Inc. (OTC:XDSL - News) is cited as one example of the way blue chip companies are acting as catalysts for accelerated commercialization of nanotechnology research.
ADVERTISEMENT





In its lead article, "Blue Chips Stack Up on Nanotech," the newsletter surveys different ways that large-cap companies promote the commercialization of nano-enhanced products. According to Forbes/Wolfe Nanotech Report, these include funding corporate research labs, academia, and nanotechnology start-ups.

mPhase is mentioned as a beneficiary of collaborative work promoted by the New Jersey Nanotechnology Consortium, which is operated by Lucent Technologies Bell Labs. Through the NJNC, Bell Labs and mPhase are developing two nano-enabled products - a "smart" battery and an ultra-sensitive magnetometer. The article is accessible from the mPhase Technologies home page, www.mphasetech.com. Online subscriptions to the Forbes/Wolfe Nanotech Report are available at https://w1.buysub.com/servlet/OrdersGateway?cds_page_id=1301… _response_key=ITM04FN&cds_mag_code=FWN (Due to its length, this URL may need to be copied/pasted into your Internet browser`s address field. Remove the extra space if one exists.)

About mPhase Technologies, Inc.

mPhase Technologies Inc. (OTC: XDSL - News) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award, is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com

[opelmanta3]

Sense Holdings Deploys Innovative Biometric Fingerprint Identification System in International Healthcare Market
Monday October 24, 4:01 pm ET
Landmark Agreement with Venezuelan Healthcare Services Provider Extends Growth Plans to Latin American Marketplace


FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct. 24, 2005--Sense Holdings, Inc. (OTCBB:SEHO - News; FWB:OUP), a developer of next-generation biometric and explosive detection security technologies for government and commercial security markets, today announced a new milestone in the completion of its successful deployment of a breakthrough biometrics-based healthcare benefits administration solution in a major Latin American market.
ADVERTISEMENT





This customized system, based upon Sense`s proprietary platform technology, has been successfully created and implemented for a customer in Venezuela, Cuidamed International, a major healthcare company.

"The customer came to us with an identification authorization problem, and we developed and deployed an effective, airtight solution," CEO Dore Perler said. The solution is called "CheckPrint Healthcare Administrator" (CPHA), and involves breakthrough identification authentication systems based on emerging fingerprint and biometrics technologies. The base technology is widely adaptable to address an extensive range of applications, and can meet the needs of very diverse US and global customers in a myriad of industries.

CPHA was developed by Sense`s development team jointly with Cuidamed International, to ensure that only properly insured individuals can seek to claim health benefits. Among the product`s functions are advanced, modernized record-keeping, and the prevention of illegal sharing of employees` private health benefits among unauthorized members. "Illegal use of benefits has resulted in substantial losses in the healthcare industry, and particularly for employers providing the benefits, degrading the quality of health care overall," said Mr. Perler. "Now, Sense has created a solution for these problems."

The enrollment process involves registering background information and specialized fingerprint imaging, in addition to photos of the authorized insured parties. In addition, CPHA keeps complete records of all medical office visits by insured parties, to further increase administrative efficiency and optimize quality of care.

Sense expedites the integration of explosives detection and biometric authentication and identification technologies into aviation, banking and finance, education, food preparation, gaming, garment, health care, hotel, insurance, law enforcement, manufacturing, military, public safety, security, restaurant, retail, and transportation applications, with industry-specific calibration. Sense also recently formed an Advisory Board to accelerate its strategic business initiatives to generate high-growth revenues in the Homeland Security marketplace. Sense is developing a portfolio of proprietary applications, including biometric security systems and explosive detection and screening devices for use at airports and other venues

[opelmanta3]

[opelmanta3]

SmallCap Sentinel: Security and Privacy Concerns Give Rise to New Technologies in Global Healthcare Marketplace
Wednesday October 26, 3:30 am ET


IRVINE, Calif., Oct. 26, 2005 (PRIMEZONE) -- ``Growing concerns over security and individual privacy are shaping the burgeoning homeland security marketplace,`` said SmallCap Sentinel Analyst, D.R. Clark. ``And there appears to be growing momentum from within the global healthcare market for ground-breaking biometric authentication technology.``
``Inventive solutions with a genesis in the post-9/11 scramble for heightened security have given rise to new technologies now gaining traction within other industries. One example is the use of biometric identification and authentication in the healthcare industry,`` said Clark. ``Both Identix Incorporated (NasdaqNM:IDNX - News) and Sense Holdings Inc. (OTC BB:SEHO.OB - News) have recently announced successful deployment of biometric-based solutions for major healthcare institutions.``

``With the recent passage of the Federal Real ID Act, the Department of Homeland Security has been granted the authority to redesign a uniform state ID card and driver license that may include, among other things, biometric information such as DNA data, retinal scans and fingerprints,`` said Clark. ``Clearly we have only seen the tip of the iceberg in biometric ID applications.``

[notebook]

Mphase: Am 03.11.05 kamen Zahlen. Diese betrafen das Geschäftsjahr 2005, das auf den 30.06.05 endet. Erwartungsgemäss ging der Umsatz zurück. "Buy on bad news, sell on good news".

- Die Q3-Ergebnisse wurden noch nicht publiziert.
- Weiter wird mphase glaube ich am 11.11.05 an einer Konferenz der NASA ihre Produkte präsentieren.
- Mphase ist immer noch auf der Naked Short List. Sowas ist natürlich nicht positiv und sollte zu denken geben. Andererseits erklärt dies m.E. den kürzlichen Kursrückgang.

Meine Prognose: Die Präsentation im Rahmen der NASA und möglicherweise positive Q3-Ergebnisse könnten dem Kurs zu neuem Auftrieb verhelfen. Wenn dann die Shortsellers zusätzlich noch die Aktien zurückkaufen, könnte es ein Kursfeuerwerk geben.

In diesem Thread hier werden Aktien differenzierter diskutiert. Von daher würde mich eine objektive und differenzierte Meinung zu Mphase interessieren. Dabei möchte ich gerne die kurzfristige Kursentwicklung der nächsten Wochen und Monate in den Vordergrund stellen.

Beste Grüsse
notebook

[nort_de]

Hallo notebook,

danke für die Infos. Freut mich, dass jemand hier wieder was posted. Weißt Du etwas mehr von der Konf.? Kann man die im Web mitverfolgen?

nort

[notebook]

Nein - interessiert mich ehrlich gesagt auch nicht. Das gibt wieder ne positive News. Punkt.

Wenn natürlich darauffolgend Gerüchte über mögliche Aufträge entstünden, wäre das natürlich interessant.

Eigentlich habe ich gehofft, dass die Teilnehmer dieses Threads ne Einschätzung geben könnten. Den Ami-Boards ist nichts Gescheites zu entnehmen. (Sind wohl alle am shorten und bashen deshalb wie wild).

Grüsse, notebook

[nort_de]

welches board meinst du?

[notebook]

och, beispielsweise ragingbull. Aber wichtig ist das auch nicht. Da kann man vielleicht mal 5% brauchen. Sonst finde ich zu mphase eigentlich nicht soviel. Oder weisst du vielleicht einen Ort, wo vernünftige Menschen über mphase diskutieren?

[nort_de]

eben auch nicht.

[notebook]

Weisst du, wann die Zahlen kommen?

[opelmanta3]

MIVT Discusses Positive Interim Research Results on Path to Commercialize New Generation Stent Coatings
Thursday November 10, 3:30 am ET
Chief Technology Officer Cites Interim Results of Long-Term Animal Studies in Anticipation of Final 6 Month Results and Report in Interview with BiomedDiscoveries.com


LOS ANGELES, Nov. 10, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today announced the availability of a new audio interview with Arc Rajtar, Chief Technology Officer of MIV Therapeutics (OTC BB:MIVT.OB - News); (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems.
ADVERTISEMENT


In the interview, Mr. Rajtar discussed recently announced interim findings of an independent, long-term animal study of MIVT`s novel technology to create new, highly biocompatible and bio-friendly coatings for vascular stents, including drug-eluting stents and other medical devices. Stents are widely used medical devices designed to prop open clogged blood vessels to maintain healthy blood flow to the heart and throughout the body, but current products are associated with a number of undesirable effects that result from insufficient biocompatibility.

``Our objective was to develop a coating which will be as biocompatible as possible and biologically safe,`` said Mr. Rajtar. ``The results from 1-month and 3-month long arms of this study confirmed our earlier expectations of superb biocompatibility and total safety of our Hydroxyapatite coatings.``

The final results of the 6 Month long study are expected next week.

MIVT has developed both ultra-thin as well as thicker, drug-eluting stent coatings based on a highly biocompatible material called Hydroxyapatite (HAp). The coatings are being conducted at the Center for Research in Cardiovascular Interventions of The Methodist Hospital Research Institute in Houston, TX. The findings were reported to the scientific community recently at the Transcatheter Cardiovascular Therapeutics 2005 conference, the field`s most important annual conference.

``In its thicker, submicron version which is also highly porous, we see our HAp coatings as exceptional vehicle for short-term and long-term drug delivery purposes,`` Mr. Rajtar said. ``This is exceptional because at the present time there is no other coating which can match the biocompatibility of Hydroxyapatite and provide drug eluting capability at the same time.``

Mr. Rajtar explained that during animal trials, MIVT`s stent coatings did not cause any adverse reactions, including excessive stenosis (re-clogging of arteries through unwanted tissue growth), and no thrombus (blood clot), both of which are growing concerns in connection with the drug-eluting systems now available for use in the health care marketplace.

The entire streaming audio interview with Mr. Rajtar can be accessed free of charge by visiting http://www.BiomedDiscoveries.com.

[nort_de]

At NASA Tech Briefs Nano 2005, mPhase Technologies Displays First Working Ultra-Sensitive Metal Detector That Requires No Cooling

NEWTON, Mass.--(BUSINESS WIRE)--Nov. 10, 2005--At this week`s NASA Tech Briefs Nano 2005 Engineering Conference and Expo here, mPhase Technologies (OTCBB:XDSL) is staging the first public display of a working ultra-sensitive metal detector that requires no cooling. This marks a significant step toward the development of a device that will be theoretically 1000 times more magnetically sensitive than comparable solutions available on the market today.

mPhase has licensed this magnetometer technology from Lucent Technologies Bell Labs and is working to commercialize the new class of magnetometers for use as un-cooled ultra-sensitive sensors for a host of possible defense and civilian applications including automated battlefield sensors and integrated compass and direction functionality in handheld devices.

Magnetometers detect changes or disturbances in magnetic fields and derive information such as presence, size, location and orientation of objects, such as metal, that have magnetic properties.

"We have had serious discussions with potential defense customers for this disruptive technology," said Ron Durando, CEO, mPhase Technologies. "We are pleased by the pace of development and these users are helping us characterize the product to meet market requirements."

This magnetometer prototype incorporates Bell Labs-designed micro-electromechanical systems (MEMS) and its sensing component is manufactured through a silicon-based process, yielding production costs that are significantly lower than with traditional magnetometers.

mPhase is a Silver Corporate Sponsor of Nano 2005, being held at The Marriott Boston Newton, Newton, Mass., Nov. 10-11.

About mPhase Technologies, Inc.

mPhase Technologies Inc. (OTCBB:XDSL) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award, is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors they believe to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

[Croatia123]

kann mir jemand bitte sagen wann Emergency Filtration die Quartalszahlen veröffentlicht????


Danke!!


Gruß
T.

[opelmanta3]

Sense Holdings Executes Agreement to Develop Next-Generation Handheld Explosive Detectors at Fraction of Cost of Current Products
Monday November 14, 4:01 pm ET
Prototype Device Expected by 1Q 2006 Under Joint Development Agreement with Oak Ridge Nat`l Laboratory


FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Nov. 14, 2005--Sense Holdings, Inc. (OTCBB:SEHO - News; FWB:OUP), a developer of next-generation biometric and explosive detection security technologies for government and commercial security markets, has executed a landmark agreement with Oak Ridge National Laboratory (ORNL) to jointly develop a very compact, handheld, real time explosive detection device with unprecedented sensitivity, at a fraction of the cost of currently available products and technologies.
ADVERTISEMENT


Sense`s proposed device is designed to provide a number of core advantages over currently available detection products for the global Homeland Security marketplace. It is expected to measure only about the size of a cell phone and weigh about two pounds - yet will possess powerful and sensitive detection technology based on Sense`s breakthrough microcantilever technology platform, a pioneering advance in the science of Micro Electromechanical Systems (MEMS).

The Company expects to have its first-generation prototype of the handheld, lightweight detection device ready by first quarter of 2006, and ready for marketing by mid-2006. Functionality of future generations of the detector will be subsequently expanded to include chemical warfare agents, biological warfare agents and narcotics, the Company anticipates. Sense owns the exclusive worldwide marketing rights for this patented technology for all security applications. Such multi-purpose detection devices will be designed to address a number of additional security market segments, including customs, law enforcement and border patrol, among other public and private markets.

"This Cooperative Research and Development Agreement (CRADA) we have entered into with Oak Ridge National Laboratories will significantly accelerate our mission to provide leading-edge, superior explosive and chemical detection innovations for government and commercial markets," said Dore Perler, CEO of Sense Holdings. "It will make accessible to customers of all sizes and with wide-ranging budgets the most advanced detection capabilities available at dramatic cost savings, possibly about one-fifth of the current cost of leading detection systems. We`ve worked with the government`s world-class Oak Ridge scientific team in the past, but this expanded CRADA now repositions us to bring leading-edge miniaturized and cost-effective detection systems to market."

Sense owns the exclusive worldwide marketing rights for all relevant technologies and applications - positioning it for high-growth revenues in multiple industries and markets. The CRADA is initially effective for a one-year term, renewable annually.

"Our partnership with Sense Holdings will enable us to move forward efficiently and quickly to develop this breakthrough technology to create a new generation of truly miniature real time detectors for explosives and other threats," said Bruce Warmack, principal investigator for ORNL. "Sense`s top management and scientific personnel have already demonstrated strong business commitment and expertise, and we are very excited to be working with them on this important homeland security product development program.

The first-generation product line will be brought to market as an explosives detection device. Subsequent generations would be further developed into comprehensive, multipurpose chemical detectors, capable of sensing a myriad of diverse threats and substances, from top chemical warfare agents to biological agents such as Anthrax, Ricin, Botulinum and others, to many narcotics that are routinely trafficked across U.S. borders, including cocaine, heroine and marijuana.

"There`s simply nothing else remotely like this device on the market," Mr. Perler said. "Sense`s explosive detection system is designed to set the new standard in terms of both cost, efficiency and effectiveness for various homeland security market segments, including counterterrorism, law enforcement and substance detection of all kinds. Its cutting-edge technology and ease-of-use advantages are expected to be significant selling points for Homeland Security agencies, Customs, Border Patrol, and innumerable other major public and private customers. Sense plans to offer its products as alternatives to today`s outdated inconvenient explosive and other detection systems."

Sense has an established umbrella of products that are successfully targeted and deployed to the Homeland Security market, including novel biometric, micro-sensor identification and RFID asset tracking solutions. Its new agreement with Oak Ridge could substantially reinforce its market edge and business strategy for accelerated, high growth revenues vis-a-vis the monetization of its valuable Intellectual Property portfolio. According to specific terms of the agreement, Sense has committed to fund the system`s development both at the ORNL and its own world-class research facilities, with a total of $1.1 million, to be divided in monthly payments of about $100,000.

Part of the funds will be dedicated to the hiring of additional scientific and technical personnel at both facilities, to expedite the collaborative development effort. In addition, a combination of U.S. agencies has dedicated about $10 million to ORNL, which will further reinforce the development of the system.

Mr. Perler added, "We will seek to deploy these units to major airports, stadiums, coliseums and the full range of strategic venues and environments that need optimized detection capabilities."

[opelmanta3]

MIVT`s Proprietary Stent Coating Technology Completes Major Long-Term Animal Study with Excellent Results
Tuesday November 15, 3:30 am ET
Six-Month Study Demonstrates Unparalleled Biocompatibility and Safety of MIVT HAp Coatings for Drug-Eluting Stent Applications


VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 15, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems, announced today that a pivotal long-term animal study of its novel stent coating technology has been concluded, with results that were unequivocally successful in demonstrating the coating`s excellent biocompatibility and safety.
ADVERTISEMENT


The 6-month study, performed by Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization, indicated that MIVT`s Hydroxyapatite-based coatings were excellent candidates for advanced drug-eluting stent coatings.

Dr. Greg L. Kaluza, MD, scientific director of the CRCI at the Methodist Hospital Research Institute, was the lead investigator for the study. Dr. Fred J. Clubb, Jr. of Texas Heart Institute served as a study pathologist.

"The study`s results are particularly encouraging for several reasons," said Dr. Kaluza. "The polymeric stent coatings that are now widely used are increasingly criticized as a suboptimal solution, because many of them may elicit prolonged foreign body response and foster platelet deposition which may in turn trigger in-stent thrombosis," he said. "In contrast, the Hydroxyapatite coating we studied is built entirely of a mineral native to the human body and as such may have a long-term biocompatibility advantage."

The results of this recently completed study indicate this coating may be safely used as a drug-eluting platform since it may be expected from the present study that the Hydroxyapatite (HAp) coating will remain inert in the arterial wall even long after the drug is completely eluted. The well-known long-term neutral effects and natural absorption of HAp coatings from orthopedic and dental implants strongly reinforce this belief. The HAp coating with microporous structure is expected to enable effective drug elution without ever involving any polymer, a design concept that is currently viewed as superior and the most attractive for drug-eluting stents."

"We now have a comprehensive set of data demonstrating that the ultra-thin Hydroxyapatite coating with a potential for use in non-polymeric and composite drug-eluting systems selected for this study has excellent biocompatibility at all three studied time points, up to as long as six months of observation," said Dr. Kaluza. "The safety profile of the studied coating is exemplary and appears at least on par with stainless steel stent surface, which remains a benchmark whose biocompatibility has not been surpassed by any coating to date."

Stents are devices implanted in the arteries to prop open the blood vessels and maintain healthy blood flow to the heart and throughout the body. MIVT has developed a next-generation line of coatings based on a substance called Hydroxyapatite (HAp), to create both passive and drug-eluting coatings designed to eliminate many of the serious problems that are associated with current generations of stent coatings.

"The study provided critical long-term data that reinforced our preliminary research that has indicated the exceptional safety and biocompatibility of our proprietary coating technologies," said Alan Lindsay, CEO of MIVT. "The uncompromised biocompatibility stands behind the potential of MIVT`s HAp coating technologies and their expected therapeutic advantages over the existing coatings and stent technologies currently available to the biomedical industry."

The successful results of the animal study will enable MIVT to plan future clinical trials to continue to advance its research and product development programs for the multi-billion-dollar global stent marketplace.

The study was conducted in a standard model of porcine coronary arteries and utilized angiography, intravascular ultrasound and histology to evaluate tissue response to HAp-coated stents in comparison to identical stainless steel stents. The study was performed in compliance with GLP (Good Laboratory Practice) guidelines, CE-Mark and FDA requirements.

MIV Therapeutics is developing a diverse suite of HAp coating formulas to enable the surface of stents and other implanted devices to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue. Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT`s HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances. HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at the TCT 2005 conference estimated that thrombogenicity was identified in 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000 premature deaths.

[opelmanta3]

[opelmanta3]

[opelmanta3]

Emergency Filtration Products In Production
Thursday November 17, 1:16 pm ET


HENDERSON, Nev.--(BUSINESS WIRE)--Nov. 17, 2005--Emergency Filtration Products Inc. (EFP) (OTCBB: EMFP - News) today announced that it is producing NanoMask filters at its new production facility in Henderson, Nev. EFP`s production crew is applying nanoparticles to precut filters and packaging them hermetically. Packaged filters, along with masks received from the company`s Taiwanese manufacturer, will be shipped to distributors and other customers shortly. The company`s immediate goal is to clear the substantial backlog that has been caused by an increase in demand for the NanoMask and the NanoMask filters.
ADVERTISEMENT


As previously stated, the company`s initial production plans call for enhancing the filters at the rate of approximately 500,000 per week. To meet the anticipated demand, EFP has ordered approximately 7 million precut filters. The company expects to take scheduled weekly deliveries of the filters through February 2006. EFP has ordered an additional 300,000 NanoMask shells from its Taiwanese manufacturer and expects delivery by December 2005. Current orders suggest that customers are purchasing approximately 20 filters for every mask.

"Now that we have our production facility in Henderson operating, we hope to clear our continuously growing backlog of orders for the NanoMask and NanoMask filters over the course of the next few weeks," said Douglas K. Beplate, president and CEO, EFP. "Additionally, we are currently in negotiations with several international distributors to address the inquiries for the NanoMask that we are receiving from other countries."

About NanoMask: (http://www.emergencyfiltration.com/ProductPage/NanoMask.htm)

EFP`s 2H Nano-Enhanced Environmental Mask, the NanoMask relies on the company`s core 2H Technology(TM) filtration system, which utilizes a combination of hydrophobic or hydrophilic filters able to capture and isolate bacterial and viral microorganisms with efficiencies of 99.9%. The environmental mask utilizes the company`s patented 2H Technology(TM) and nanotechnology to enhance the capture-and-isolation characteristics of the filter media.

About Emergency Filtration Products: (http://www.emergencyfiltration.com/)

EFP is an air filtration products manufacturer whose patented 2H Technology(TM) filter system has produced filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027 microns. Its initial products were developed for the medical market: the Vapor Isolation Valve(TM) and RespAide® CPR Isolation Mask used for resuscitation of respiratory/cardiac arrest cases; and the 2H Breathing Circuit Filter for ventilators, respirators and anesthesia circuitry. Each has received FDA approval. The company also markets an Automated External Defibrillator Prep Kit featuring RespAide; and the NanoMask®, a nanotechnology enhanced environmental mask. In addition to filtration products, the company supplies Superstat®, a modified hemostatic collagen; to the U.S. military for surgery and extreme wound care.

[opelmanta3]

XDSL (RFID NANOTECH ....)
http://www.mphasetech.com

http://www.mphasetech.com/ForbesWolfe.pdf

EMFP (NANOMASK)
http://www.emergencyfiltration.com/Product%20Page/Products.h…

MIVT ( HAp Nano-film Coating Technology )
http://www.mivtherapeutics.com/

SEHO (Homeland Security, and Nanotechnology)
http://www.senseme.com/scripts/about.htm

[opelmanta3]

nanotechs laufen heute ganz gut

besonders NANX
ARWR wenn sie die 5 knacken

[boom2]

Dear Sharpeyed.com subscribers,


This year we have Scientific American releasing their feature article about XDSL during the month of February !!!

Check out this ScienCentral article and video from a year ago about XDSL`s nanobattery:

www.sciencentral.com/articles/view.php3?article_id=218392466

Once Scientific American hits newsstands next month the ENTIRE WORLD will be talking about XDSL! Then when ScienCentral airs their update on TV it is unimaginable how much publicity XDSL is going to have!!!!!!!

The investment community is totally unaware of XDSL stock! It is unbelievable that XDSL is trading at valuations this low! These next couple of weeks will be the biggest weeks in the history of the company!!! We need to help spread the word!!!!

--------------------


Sharpeyed.com tries to identify stocks poised to break out to the upside before they happen for maximum returns. We only invest in the long side of the market, we buy low to sell higher. Use appropriate risk management with all your investments. Please always set the stop orders to protect your profit.

Please be aware that unexpected news or world events can substantially change the direction of a stock. We don`t like to make exact price targets, this only locks investors mentally into a number. It is up to you to take profits where you are comfortable.


Best regards,


Sharpeyed.com Staffs
http://sharpeyed.com
[e-mail]
Please be sure that you have read and fully understood our disclaimer: http://sharpeyed.com/disclaimer.htm

XDSL update (strong Buy Alert):

XDSL has tons of insider buying.

Insiders are buying for a very good reason!

XDSL is the first company to ever become involved with the reinvention of the battery.

XDSL will be able to make their nanobatteries so small that they can be built with the other circuitry on a chip.

XDSL`s nanobatteries will also have unlimited shelf life since they will only use power when the device is activated.

Eventually we expect all cell phones to have XDSL`s nanobatteries built inside as a backup reserve battery to give you extra talk time.

we expect XDSL to combine their nanobatteries with their nano metal detectors to help the military develop tiny sensors that will be dropped from aircraft to signal the presence of intruders on the ground.

This year we have Scientific American releasing their feature article about XDSL during the month of February!!!

Check out this ScienCentral article and video from a year ago about XDSL`s nanobattery:

www.sciencentral.com/articles/view.php3?article_id=218392466

Once Scientific American hits newsstands next month the ENTIRE WORLD will be talking about XDSL! Then when ScienCentral airs their update on TV it is unimaginable how much publicity XDSL is going to have!!!!!!!

Trust Sharpeyed.com, XDSL is a sure thing. Sharpeyed.com is not being compensated in any way for covering XDSL and Sharpeyed.com owns no stock in the company. We are just telling you our honest opinion.


--------------------------------------------------------------------------------

[BadJonas]

Diese Aktie scheint keinen zu intressieren.
Na dann muß ich eben alleine mit dem Anstieg leben.

[BadJonas]

Aktie wird nicht beachtet
Performance
Zeitraum Performance Ø Volumen pro Tag
1 Woche +11,19% 2.941.890
4 Wochen +59,80% 3.324.822

[opelmanta3]

ja ist ganz gut...aber ich finde sie sollte viel mehr abgehen...alti hat heute schon wieder news zu ihren nanobatteries abgeliefert....

wenn XDSL eine rausgibt wird sich das teil wieder verdoppeln...

MIVT sieht heute leider recht scheise aus....

[opelmanta3]

zurück zu .60?

[opelmanta3]

MIV Therapeutics Executes Agreement to Collaborate on Future Drug Eluting Stent Technologies with Sahajanand
Friday February 3, 5:01 pm ET
Agreement with Stent Manufacturer to Involve Potential Cross-Licensing and Other Development Initiatives


VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 3, 2006--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has entered a collaborative agreement with Sahajanand Medical Technologies, a manufacturer of stents and drug-eluting stents.
ADVERTISEMENT


Under the terms of the agreement, MIVT and Sahajanand will collaborate to develop products based on the two companies` advanced technologies and solutions for the worldwide vascular stent marketplace. The partnership may involve a number of potential business and technology initiatives to commercialize MIVT`s line of biocompatible coatings. MIVT`s unique biocompatible medical device coatings are designed to improve the performance and safety of billions of dollars worth of stents, drug-eluting stents and other medical devices that are implanted in patients each year.

The strategic collaboration supersedes MIVT`s previously announced letter of intent to acquire Sahajanand in a stock-based transaction. Since the newly announced collaboration will not require the Company to issue the approximately 53 million new shares that would have been used in an acquisition of Sahajanand, significant shareholder dilution will be avoided.

"We believe this newly announced collaborative approach will best serve MIVT and its shareholders. It will give MIVT access to Sahajanand`s value as a strategic partner, as well as their global market presence, without requiring the high expense and shareholder dilution of an acquisition," said Alan P. Lindsay, CEO of MIVT. "In light of MIVT`s better-than-anticipated growth in market capitalization and our scientific development during the last year, and following thorough due-diligence with respect to the proposed acquisition of Sahajanand, both managements have concluded that this restructured strategic partnership, rather than acquisition, is the most advantageous path."

Mr. Lindsay further explained: "In the year since our initial agreement to explore the acquisition of Sahajanand, MIVT has progressed and evolved substantially as a Company, both in terms of our technology and in the growth of shareholder value. At last count we had expanded our intellectual property portfolio to a total of 43 U.S. and international patents and patent applications. We`ve met and exceeded all key important scientific and clinical development milestones in development of our biocompatible coatings and drug-delivery systems, and we have been invited to report on our research and development progress at leading industry conferences. In addition the significance and potential value of our technology to the worldwide stent and medical device marketplace has been recognized by independent industry analysts, including the prestigious Frost & Sullivan 2005 Award for Technology Innovation in the Field of Medical Coatings. In light of this progress, Management decided that this strategy will provide us with the highest degree of flexibility in executing our research and development programs and our strategic business initiatives."

Dhirajlal Kotadia, founder and CEO of Sahajanand, said the agreement was designed to provide valuable mutual benefits to both companies, by creating synergies between both Companies` cutting-edge technologies and products. "I believe this partnership will enable us to develop important solutions for the worldwide cardiovascular marketplace for stents and advanced drug-eluing stents," he said.

[Phantomas2]

[posting]19.997.765 von BadJonas am 01.02.06 19:07:24[/posting]Hallo Bad,

ich bin auch dabei, die Aktie hat ein super Chart, und ich denke das es erst der Anfang ist. Ich denke, das wir in 1-2 Jahren Kurse sehen werden, die uns sehr glcklich machen werden.
Ich hoffe auch, das ihr keine Zocker mehr aufspringen, ansonsten kann es auch wieder viel Kaputt machen, und daher denke ich das dieser Wert noch hoffentlich lange unendeckt bleibt. ( nur von Zockern unendeckt bleibt)!

Ich persönlich werde diese Aktie bis zu 3-4 Jahren halten, was auch kommen mag. Ich denke das diese Aktie erst in einem Jahr da stehen wird wo sie auch hin gehört.

Aber jeder soll seine eigene Meinung zu dieser Aktie haben, ich bin aufjedefall schon fast ein Jahr investiert, und bin auch gut im Plus, aber ich denke das es mir in Zukunft noch sehr glücklich machen wird.

Aufjedenfall werde ich moantatlich schreibe, dann sehen wir ob ich auf dem richtigen Weg bin.

See you later

Steve

PS: Diese Aktie ist mein absoluter Geheimtipp für die Zukunft, an zweiter stelle steht MIV Thera....
und an dritter Stelle Maui General Store,
da werden wir in den nächsten 3 Jahren Kurse sehen, wo sich jetzt noch niemand vorstellen kann.

In diesem Sinne schönes Wochenende

[opelmanta3]

Web Alert: Sense Holdings to Premiere Next-Generation MEMS Technology in Video Presentation TODAY at 12:00 noon -ET-
Friday February 17, 3:30 am ET
Proprietary MEMS-based Platform Featured for Homeland Security Applications and Detection Solutions


FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Feb. 17, 2006--Sense Holdings, Inc. (OTCBB:SEHO - News; FWB:OUP), a developer of next-generation biometric and explosive detection security technologies for government and commercial security markets, will present a detailed technology overview regarding their proprietary MEMS-based applications in an online video, scheduled to start at 12 noon Eastern, Today.
MEMS structures are fabricated in a similar fashion to mass-produced electronic integrated circuits and can be applied to the detection of a wide range of illicit and dangerous threats, including explosives, chemical warfare agents, biological warfare agents and narcotics. Eventually, Sense intends to commercialize a full pipeline of novel detection devices capable of sensing many of these threats and substances.

To view the video, register online as explained below. There is no charge to register or watch the video. Webcast information is as follows:

What: This live over-the-Internet video presentation features an
on-camera presentation by Sense Holdings CEO Dore Perler,
with informational slides and animations.

When: Friday, February 17, 2006, at 12 noon Eastern.

Where: Please register at:
http://www.trilogy-capital.com/tcp/sense/mems_video.html." target="_blank" rel="nofollow ugc noopener">http://www.trilogy-capital.com/tcp/sense/mems_video.html.
Simply log on and you will be able to view the webcast.
Refresh your browser if video fails to initiate or
viewing difficulties occur.

Cost: The conference is free of charge and open to all
interested investors.

Archive: If you are unable to view the initial webcast, the
Forum will be archived for replay at
http://www.trilogy-capital.com/tcp/sense/mems_video.html

[Joman0]

Hm, wenn ich mal die Technologie von A123Systems anschaue, dann sind die doch schon ein wenig weiter. Der Vorteil liegt im Einsatzbereich. Die Nanobatterie von A123Systems wird auch für Hybrid-und Elektroautos gebraucht werden können. Ich finde leider keine WKN dieser Firma. Sind die gar nicht notiert?
Cu joman0

[opelmanta3]

das liegt daran das sie private sind...vielleicht wäre es ja möglich soch mit 1 million VC zu beteiligen...

ansonsten vielleicht doch XDSL...

[tobijack]

heute wieder im AKTIONÄR als kaufgelegenheit mit attraktiven einstiegsniveau